



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number : **0 478 363 A2**

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number : **91308850.6**

⑮ Int. Cl.⁵ : **C07D 211/22, C07D 409/12,
C07C 311/13, C07C 311/19,
A61K 31/445**

⑭ Date of filing : **27.09.91**

⑯ Priority : **27.09.90 US 589130
30.08.91 US 750647**

⑰ Date of publication of application :
01.04.92 Bulletin 92/14

⑲ Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

⑳ Applicant : **MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0900 (US)**

㉑ Inventor : **Egbertson, Melissa S.
1232 Lois Road
Ambler, PA 19002 (US)**

Inventor : **Laswell, William L.
433 Dorchester Lane
Perkasie, PA 18944 (US)**
Inventor : **Hartman, George D.
1529 Tennis Circle
Lansdale, PA 19446 (US)**
Inventor : **Duggan, Mark E.
300 North Essex Avenue, Apt. 205B
Narberth, PA 19072 (US)**
Inventor : **Halzenko, Wasyl
1003 Clymer Road
Hatfield, PA 19440 (US)**

㉒ Representative : **Barrett-Major, Julie Diane et al
Merck & Co., Inc. European Patent
Department Terlings Park Eastwick Road
Harlow Essex CM20 2QR (GB)**

㉓ Novel sulfonamide fibrinogen receptor antagonists.

㉔ A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.

EP 0 478 363 A2

Jouve, 18, rue Saint-Denis, 75001 PARIS

EV 726255925 US

Atty. Docket No. 3078/4/US
Serial No. 10/016,146
Cunningham, et al.
Reference 14

BACKGROUND OF THE INVENTION

The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, such compounds being generally pharmacologically useful as anti-platelet aggregation agents in various vascular pathologies. The aforementioned pharmacologic activities are useful in the treatment of mammals. More specifically, the sulfonamide compounds of the present invention act by blocking the molecular receptor site of the protein fibrinogen. Fibrinogen is a glycoprotein that circulates in the blood plasma, and whose platelet receptor site is glycoprotein IIb/IIIa. By blocking the action of fibrinogen at the receptor (glycoprotein IIb/IIIa), the compounds of the present invention interfere with platelet aggregation, which is a cause of many vascular pathologies. At the present time, there is a need in the area of vascular therapeutics for such a fibrinogen receptor blocking agent. By interfering with hemostasis, such therapy would decrease the morbidity and mortality of thrombotic disease.

Hemostasis is the spontaneous process of stopping bleeding from damaged blood vessels. Precapillary vessels contract immediately when cut. Within seconds, thrombocytes, or blood platelets, are bound to the exposed matrix of the injured vessel by a process called platelet adhesion. Platelets also stick to each other in a phenomenon known as platelet aggregation to form a platelet plug. This platelet plug can stop bleeding quickly, but it must be reinforced by the protein fibrin for long-term effectiveness, until the blood vessel tear can be permanently repaired by growth of fibroblasts, which are specialized tissue repair cells.


An intravascular thrombus (clot) results from a pathological disturbance of hemostasis. The thrombus can grow to sufficient size to block off arterial blood vessels. Thrombi can also form in areas of stasis or slow blood flow in veins. Venous thrombi can easily detach portions of themselves called emboli that travel through the circulatory system and can result in blockade of other vessels, such as pulmonary arteries. Thus, arterial thrombi cause serious disease by local blockade, whereas venous thrombi do so primarily by distant blockade, or embolization. These diseases include venous thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis and myocardial infarction, stroke, cerebral embolism, kidney embolisms and pulmonary embolisms.

There is a need in the area of cardiovascular and cerebrovascular therapeutics for an agent which can be used in the prevention and treatment of thrombi, with minimal side effects, including unwanted prolongation of bleeding in other parts of the circulation while preventing or treating target thrombi. The compounds of the present invention meet this need in the art by providing therapeutic agents for the prevention and treatment of thrombi.

The compounds of the present invention show efficacy as antithrombotic agents by virtue of their ability to block fibrinogen from acting at its platelet receptor site and thus prevent platelet aggregation.


35 SUMMARY OF THE INVENTION

The present invention relates to novel compounds having the general structural formula I :




50 and the pharmaceutically acceptable salts thereof, wherein
R¹ is,

a four to eight member heterocyclic ring containing 1, 2, 3 or 4 heteroatoms wherein said hetero atoms are N, O or S and wherein said hetero ring is optionally substituted at any atom by H, R⁶ or R⁷; NR⁶R⁷



5



wherein R⁸ and R⁷ are independently hydrogen and unsubstituted or substituted C₀₋₁₀ alkyl and cycloalkyl wherein said substituents are

10 C₁₋₁₀ alkoxy,
C₁₋₁₀ alkoxyalkyl,
C₁₋₁₀ alkoxyalkyloxy,
C₁₋₁₀ alkoxy carbonyl,
C₁₋₁₀ alkyl carbonyl,
15 C₄₋₁₀ aralkyl carbonyl,
C₁₋₁₀ alkylthiocarbonyl,
C₁₋₁₀ aralkylthiocarbonyl,
thiocarbonyl,
20 C₁₋₁₀ alkoxythiocarbonyl,
aryl,
a 5 to 6 membered saturated heterocyclic ring containing 1,2,3 or 4 hetero atoms wherein said heteroatoms are taken from the group consisting of N, O and S,
C₁₋₄ alkanoyl amino,
25 C₁₋₈ alkoxy carbonyl-C₀₋₆ alkyl amino,
C₁₋₁₀ alkylsulfonyl amino,
C₄₋₁₀ aralkylsulfonyl amino,
C₄₋₁₀ aralkyl,
30 C₁₋₁₀ alkaryl,
C₁₋₁₀ alkylthio,
C₄₋₁₀ aralkylthio,
C₁₋₁₀ alkylsulfinyl,
C₄₋₁₀ aralkylsulfinyl,
35 C₁₋₁₀ alkylsulfonyl,
C₄₋₁₀ aralkylsulfonyl,
aminosulfonyl,
C₁₋₁₀ alkylaminosulfonyl,
C₄₋₁₀ aralkylsulfonyl amino,
40 oxo,
thio,
unsubstituted and mono- and di-substituted 1-ethenyl, 2-ethenyl and 3-propenyl wherein said substituents are selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀ aralkyl,
carboxy,
45 hydroxy,
amino,
C₁₋₈ alkyl amino,
C₁₋₈ dialkyl amino,
halogen, where halogen is defined as F, Cl, Br or I,
50 nitro, and
cyano,

and further wherein said N can additionally be substituted to form a quaternary ammonium ion wherein said substituent is as previously defined for R⁶ and R⁷;


55 R² and R³ are independently
hydrogen,
aryl and
unsubstituted and substituted C₀₋₁₀ alkyl and cycloalkyl wherein said substituent is C₁₋₁₀ alkoxyalkyl, aryl,

a 4 to 8 membered saturated heterocyclic ring system containing 1, 2, 3 or 4 heteroatoms, wherein said heteroatoms are taken from the group consisting of N, O and S,

5 C₄₋₁₀ aralkyl,
 C₁₋₁₀ alkaryl,
 C₁₋₁₀ alkylthio,
 C₄₋₁₀ aralkylthio,
 C₁₋₁₀ alkylsulfinyl,
 C₄₋₁₀ aralkylsulfinyl,
 C₁₋₁₀ alkylsulfonyl,
 C₄₋₁₀ aralkylsulfonyl,
 carboxy,
 C₁₋₁₀ alkylcarbonyl,
 C₁₋₁₀ alkylthiocarbonyl,
 C₄₋₁₀ aralkylcarbonyl,
 C₄₋₁₀ aralkylthiocarbonyl,
 C₁₋₆ alkoxy carbonyl,
 C₄₋₁₀ aralkoxy carbonyl,
 C₁₋₆ alkoxy,
 C₁₋₆ alkoxy carbonyl-C₁₋₄ alkyl,
 C₄₋₁₀ aralkoxy carbonyl-C₁₋₄ alkyl,
 C₄₋₁₀ aralkoxy,
 C₁₋₆ alkylamino,
 C₁₋₁₂ dialkylamino,
 C₁₋₆ alkanoylamino,
 C₄₋₁₀ aralkanoylamino,
 C₄₋₁₀ aralkylamino,



30 R⁴ is
 aryl,
 C₁₋₁₀ alkyl or cycloalkyl,
 C₄₋₁₀ aralkyl,
 C₁₋₁₀ alkoxyalkyl,
 C₁₋₁₀ alkaryl,
 C₁₋₁₀ alkylthioalkyl,
 C₁₋₁₀ alkoxythioalkyl,
 C₁₋₁₀ alkylamino,
 C₄₋₁₀ aralkylamino,
 C₁₋₁₀ alkanoylamino,
 C₄₋₁₀ aralkanoylamino
 C₁₋₁₀ alkanoyl,
 C₄₋₁₀ aralkanoyl, and
 unsubstituted or substituted C₁₋₁₀ carboxyalkyl wherein said substituent is aryl or C₁₋₁₀ aralkyl; further
 45 wherein any of the substituents for R⁴ may be substituted by substituents selected from the group as defined
 for R⁶;

50 R⁵ is
 a four to eight member saturated or unsaturated heterocyclic ring containing 1, 2, 3 or 4 heterocyclic
 atoms wherein said heteroatoms are N, O and S and







wherein R^8 is
 hydroxy,
 C_{1-10} alkyloxy,
 C_{1-10} alkarylloxy,
 C_{4-10} aralkyloxy,
 C_{4-10} aralkylcarbonyloxy,
 C_{1-10} alkoxyalkyloxy,
 C_{1-10} alkoxyalkylcarbonyloxy,
 C_{1-10} alkoxyalkylcarbonylalkyl,
 C_{1-10} alkylcarbonyloxyalkyloxy,
 an L- or D-amino acid joined by an amide linkage or
 an L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino
 acid is esterified by C_{1-6} alkyl or C_{4-10} aralkyl,
 20



wherein R^9 and R^{10} are selected from the group consisting of hydrogen, C_{1-10} alkyl and C_{4-10} aralkyl;
 X and Y optional substituents that, when present are independently



45 R^6R^7
 $-C=C-,$
 $-C\equiv C-,$
 a 4- to 8-membered ring containing 0,1,2,3, or 4 heteroatoms chosen from N, O and S, wherein said ring is independently substituted at any atom with R^6 ,
 aryl,



or

Z is an optional substituent that, when present, is independently chosen as defined for X and Y;


m is an integer of from zero to ten;

n is an integer of from zero to ten; and

5 p is an integer of from zero to three.

A preferred group of compounds of the present invention are those defined for general structural formula II as:

10



15

20 wherein

R1 is

a five to six member heterocyclic ring wherein said heteroatoms are N, O or S and wherein said heterocyclic ring is optionally substituted by C₁₋₆ alkyl; or

25

NR⁸R⁷ wherein R⁸ and R⁷ are independently hydrogen,unsubstituted or substituted C₁₋₁₀ alkyl wherein said substituent isC₁₋₁₀ alkoxy carbonyl,

aryl,

C₀₋₆ dialkylamino-C₁₋₁₀ alkyl,C₄₋₁₀ aralkyl,

30

and further wherein said N can additionally be substituted to form a quaternary ammonium ion wherein said substituent is as previously defined for R⁸ and R⁷;R² and R³ are

hydrogen and

C₁₋₄ alkyl, C₄₋₁₀ aralkyl;

35

R⁴ is

aryl,

C₁₋₁₀ alkyl or cycloalkyl,C₄₋₁₀ aralkyl,

40

C₁₋₁₀ alkoxy alkyl,C₁₋₁₀ alkaryl,unsubstituted or substituted C₁₋₁₀ carboxy alkyl wherein said substituent is aryl, C₁₋₆ alkyl, or C₄₋₁₀ aralkyl;R¹¹ is

hydrogen or

45


C₁₋₁₀ alkyl;

X and Y are independently

aryl,

O, SO₂,

50



a 5 or 6-membered ring containing 0, 1 or 2 heteroatoms chosen from N or O;


55

Z is an optional substituent that, when present, is

O, SO₂, -NR⁸CO-, -CONR⁸-,C₁₋₁₀ straight or branched alkyl;

m is an integer of from zero to eight;
 n is an integer of from zero to two; and
 p is an integer of from zero to two.

5 A more preferred group of compounds of the present invention are those defined for general structure formula III as



wherein

R¹ is

15 a five or six membered heterocyclic ring wherein said heteroatoms are N and O and wherein said heterocyclic ring is optionally substituted by C₁₋₅ alkyl;

NR⁶R⁷ wherein R⁶ and R⁷ are independently

C₁₋₁₀ alkyl, or

C₄₋₁₀ aralkyl

20 and further wherein said N can additionally be substituted to form a quaternary ammonium ion wherein said substituent is as previously defined for R⁶ and R⁷;

R⁴ is

aryl,

C₁₋₁₀ alkyl or cycloalkyl, or


C₄₋₁₀ aralkyl;

25 X and Y are independently

phenyl

O, SO₂

30



35 or a 5- or 6- membered ring containing 0 or 1 heteroatoms chosen from N or O;

Z is an optional substituent that, when present, is

O, SO₂, -NR⁶CO-, -CONR⁶-, or -CH₂-; and

m is an integer of from zero to six.

40 **DETAILED DESCRIPTION OF THE INVENTION**

The term "pharmaceutically acceptable salts" shall mean non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following salts:

45 Acetate
 Benzenesulfonate

Benzoate

Bicarbonate

Bisulfate

50 Bitartrate

Borate

Bromide

Calcium Eddetate

Camsylate

Carbonate

Chloride

55 Clavulanate

	Citrate
	Dihydrochloride
	Edeate
	Edisylate
5	Estolate
	Esylate
	Fumarate
	Gluceptate
	Gluconate
10	Glutamate
	Glycolylarsanilate
	Hexylresorcinate
	Hydrabamine
	Hydrobromide
15	Hydrochloride
	Hydroxynaphthoate
	Iodide
	Iothionate
	Lactate
20	Lactobionate
	Laurate
	Malate
	Maleate
	Mandelate
25	Mesylate
	Methylbromide
	Methylnitrate
	Methylsulfate
	Mucate
30	Napsylate
	Nitrate
	Oleate
	Oxalate
	Pamaote
35	Palmitate
	Pantothenate
	Phosphate/diphosphate
	Polygalacturonate
	Salicylate
40	Stearate
	Subacetate
	Succinate
	Tannate
	Tartrate
45	Teoclate
	Tosylate
	Triethiodide
	Valerate

The term "pharmacologically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician. The term "anti-coagulant agent" shall include aspirin, heparin and warfarin. The term "fibrinolytic agent" shall include streptokinase and tissue plasminogen activator.

The term "aryl" shall mean a mono- or polycyclic ring system composed of 5- and 6- membered aromatic rings containing 0, 1, 2, 3, or 4 heteroatoms chosen from N, O, and S and either unsubstituted or substituted with R⁶.

The term "alkyl" shall mean straight or branched chain alkane, alkene or alkyne.

The term "alkoxy" shall be taken to include an alkyl portion where alkyl is as defined above.

The terms "aralkyl" and "alkaryl" shall be taken to include an alkyl portion where alkyl is as defined above

and to include an aryl portion where aryl is as defined above.

The term "halogen" shall include fluorine, chlorine, iodine and bromine.

The term "oxo" shall mean the radical =O.

The term "thio" shall mean the radical =S.

5 Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. They are useful in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and thromboemboli. They may be administered to these surgical patients to prevent the formation of thrombi and thromboemboli.

10 Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between GPIIb/IIIa on the platelet membranes and fibrinogen adsorbed to the surface of the circuit. (Gluszko et. al., Amer. J. Physiol., 1987, 252:H, pp 615-621). Platelets released from artificial surfaces show impaired hemostatic function. Compounds of the invention may be administered to prevent adhesion.

15 Other application of these compounds include prevention of platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism and reocclusion after angioplasty of coronary and other arteries and after coronary artery bypass procedures. They may also be used to prevent myocardial infarction.

20 The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous, intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent.

25 The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

30 Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1.0 to 50 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

35 In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

40 For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

45 The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be for-

med from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, 5

pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

10 The compounds of the present invention can also be co-administered with suitable anti-coagulant agents or thrombolytic agents to achieve synergistic effects in the treatment of various vascular pathologies.


15 The compounds of formula I can be prepared readily according to the following reaction Schemes and Examples or modifications thereof using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail.

20 The most preferred compounds of the invention are any or all of those specifically set forth in these examples. These compounds are not, however, to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative 25 procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless noted otherwise.


Reagent symbols have the following meanings:

25 BOC: t-butyloxycarbonyl
 Pd-C: Palladium on activated carbon catalyst
 DMF: Dimethylformamide
 DMSO: Dimethylsulfoxide
 CBZ: Carbobenzyloxy
 30 CH_2Cl_2 : Methylene chloride
 CHCl_3 : Chloroform
 EtOH: Ethanol
 MeOH: Methanol
 EtOAc: Ethyl acetate
 35 HOAc: Acetic acid
 THF: Tetrahydrofuran

The source for the following compounds is as shown:



is described below.




50 2-(4-N-t-Butyloxycarbonylpiperidinyl)ethanol

4-Piperidine-2-ethanol (Available from Aldrich) (130 g, 1.0 mole) was dissolved in 700 mL dioxane, cooled to 0° C and treated with 3 N NaOH (336 mL, 1.0 mole), and di-t-butylcarbonate (221.8 g, 1.0 mole). The ice bath was removed and the reaction stirred overnight. The reaction was concentrated, diluted with water and extracted with ether. The ether layers were combined, washed with brine, dried over MgSO_4 , filtered and evaporated to give 225.8 g of product (98%).

R_f = 0.37 in 1:1 EtOAc/Hexanes, ninhydrin stain


^1H NMR (300MHz, CDCl_3) δ 4.07 (bs, 2H), 3.7 (bs, 2H), 2.7 (t, J = 12.5 Hz, 2H), 1.8-1.6 (m, 6H), 1.51 (s, 9H),

1.1 (ddd, $J = 4.3, 12.5, 12$ Hz, 2H).



Methyl 4-(4-N-t-butyloxycarbonylpiperidinyl)-but-2-enoate

Oxalyl chloride (55.8 mL, 0.64 mole) was dissolved in 1 L CH_2Cl_2 and cooled to -78°C under N_2 . DMSO (54.2 mL, 0.76 mole) was added dropwise. After gas evolution had ceased, 2-(4-N-t-butyloxycarbonylpiperidinyl)ethanol (102.5 g, 0.45 mole) dissolved in 200 mL CH_2Cl_2 was added over 20 minutes. After stirring an additional 20 minutes, triethylamine (213 mL, 1.53 mole) was added dropwise and the cold bath removed. After 1 and 1/2 hours TLC showed starting material gone. Carbomethoxytriphenylphosphorane (179 g, 0.536 mole) was added and the reaction stirred overnight. The solution was diluted with 300 mL Et_2O , extracted once with 800 mL H_2O , twice with 300 mL 10% KHSO_4 solution, then once with 300 mL brine. The organic layer was dried over MgSO_4 , filtered and evaporated. Column chromatography (SiO_2 , 5% $\text{EtOAc}/\text{Hexanes}$) yielded 78.4 g (62%) of pure methyl 4-(4-N-t-butyloxycarbonylpiperidinyl)but-2-enoate.
 $^1\text{H NMR}$ (300MHz, CDCl_3) δ 6.9 (ddd $J = 15.6, 7.6, 7.6$ Hz, 1H), 5.8 (d, $J = 15.6$ Hz, 1H), 4.0 (bs, 2H), 3.7 (s, 3H), 2.6 (t, $J = 12.6$ Hz, 2H), 2.1 (t, $J = 7.4$ Hz, 2H), 1.7-1.4 (m, 3H), 1.4 (s, 9H), 1.1 (m, 2H).



4-(4-N-t-Butyloxycarbonylpiperidinyl)butyl bromide

Methyl 4-(4-N-t-butyloxycarbonylpiperidinyl)but-2-enoate (36.2 g, 0.128 mole), was dissolved in 500 mL EtOAc . 10% Palladium on carbon (10 g) was added as a slurry in EtOAc and the reaction was placed under H_2 (in a balloon) overnight. The reaction was filtered through Solka-Floc, the cake washed with EtOAc and the ethyl acetate evaporated to give 34.7 g (90%) of methyl 4-(4-N-t-butyloxycarbonylpiperidin-4-yl)butanoate. TLC $R_f = 0.69$ in 30% $\text{EtOAc}/\text{Hexanes}$.

$^1\text{H NMR}$ (300MHz, CDCl_3) δ 4.0 (bs, 2H), 3.6 (s, 3H), 2.60 (t, $J = 12.3$ Hz, 2H), 2.20 (t, $J = 7.4$, 2H), 1.6 (m, 4H), 1.40 (s, 9H), 1.40 (m, 1H), 1.20 (m, 2H), 1.0 (m, 2H).

The butanoate ester (45.3 g, 0.159 mole) was dissolved in CH_3OH and treated with 1 N NaOH (500 mL, 0.5 mole) overnight. The solvent was removed in vacuo, water was added and the solution washed with ether, then acidified with 10% KHSO_4 solution. The aqueous layer was washed with ether, the ether layers were combined, washed with brine, dried (MgSO_4), and concentrated to give the corresponding acid as a clear oil (41.85 g, 97% yield).

$^1\text{H NMR}$ (300MHz, CDCl_3) δ 4.0 (bs, 2H), 2.6 (m, 2H), 2.25 (m, 2H), 1.6 (bs, 4H, 1.4 (s, 9H), 1.3-0.9 (9H).

This acid (20.4 g, 0.077 mole) was treated with borane (BH_3/THF , 235 mL, 235 mmole) in THF at 0° for 1 hour. NaOH (1N, 250 mL) was added dropwise and the solution stirred overnight. The resulting reaction mixture was concentrated to remove THF and extracted with ether. The ether extracts were combined, dried over MgSO_4 , filtered and evaporated to give the corresponding alcohol as 19.7 g of a colorless oil. $R_f = 0.7$ in 2:1 ethyl acetate/hexanes.

$^1\text{H NMR}$ (300MHz, CDCl_3) δ 4.1 (bs, 2H), 3.6 (t, 2H), 2.65 (t, 2H), 2.1 (bs, 1H), 1.65 (bs, 2H), 1.55 (m, 2H), 1.4 (s, 9H), 1.35 (m, 3H), 1.25 (m, 2H), 1.1 (m, 2H).

This alcohol (19.7 g, 76.5 mmole) was dissolved in THF and treated with triphenylphosphine (23.1 g, 88 mmole) and cooled to 0°C . Carbon tetrabromide (29.8 g, 89.9 mmol) was added in one portion, the cold bath was removed and the reaction stirred overnight. Additional triphenyl phosphine (11.71 g) and carbon tetrabromide (14.9 g) was added to drive the reaction to completion. The mixture was filtered and the liquid was diluted with ether and filtered again. After solvent removal the resulting liquid was adsorbed onto SiO_2 and

chromatographed with 5% EtOAc/Hexanes to yield 4-(4-N-t-butyloxycarbonylpiperidin-4-yl)butyl bromide as a clear colorless oil (20.7 g, 85% yield).


R_f = 0.6 in 1:4 ethyl acetate/hexanes

⁵ ¹H NMR (300MHz, CDCl₃) δ 4.1 (bs, 2H), 3.4 (t, 2H), 2.65 (t, 2H), 1.85 (m, 2H), 1.65 (bd, 2H), 1.4 (s, 9H), 1.35 (m, 2H), 1.3 (m, 3H), 1.1 (m, 2H).

2.BocNH(CH₂)₆Br

Commercial H₂N(CH₂)₅CH₂OH was protected as the N-Boc derivative in standard fashion and this was converted to the bromide with Ph₃P/CBr₄ in THF. Utilization of starting amino alcohols of varying chain lengths provides the analogous halides in this manner.

10




Purchased from Sigma.

20



was N-Boc protected in the standard manner.


25




was N-Cbz protected in the standard fashion and converted to final product as described in US Serial No. 589,145.


SCHEME 1

35




50






EXAMPLE 1

2-S-(Benzylloxycarbonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid (1-2)

N-CBZ-L-tyrosine (1-1) (17.58 g, 0.055 mmole) was dissolved in DMF (75 mL), cooled to 0-10° C and treated with sodium hydride (2.88 g, 0.12 mole). This suspension was stirred at 0-10° C for 1 hour and then N-t-butyloxycarbonylpiperidin-4-ylbutyl bromide (17.70 g, 0.055 mole) in 25 mL DMF was added dropwise over 15 minutes. The reaction mixture was then stirred at room temperature for 16 hours. The solvent was removed in vacuo and the residue was taken up in a mixture of 500 mL EtOAc/100 mL 10% KHSO₄. The organic phase was washed with brine, dried (Na₂SO₄) and the solvent was removed to give a viscous oil. This was purified by flash chromatography on silica gel eluting with 98:2:0.5 CHCl₃/CH₃OH/HOAc to give pure 1-2 (23.75 g), R_f = 0.35, as a pale yellow oil.

¹H NMR (300MHz, CDCl₃) δ 1.00-1.15 (2H, m), 1.20-1.80 (16H, m), 2.62 (2H, t), 3.10 (2H, m), 3.91 (2H, t), 4.04 (2H, m), 5.10 (2H, m), 5.22 (1H, d), 6.78 (2, d), 7.04 (2H, d), 7.35 (5H, m).


EXAMPLE 2

Methyl 2-S-(Benzylloxycarbonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid (1-3)

1-2 (10.05 g, 18.1 mmole) was dissolved in CH₃OH (150 mL) at room temperature and cesium carbonate (2.95 g, 9.06 mmole) was added and the resulting mixture stirred for 15 minutes to give a clear solution. The CH₃OH was removed at reduced pressure and the residue was then dissolved in DMF (150 mL) and treated dropwise with methyl iodide (2.57), 18.1 mmole). The resulting solution was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was taken up in 400 mL ether and washed with 3 x 50 mL portions of H₂O, 50 mL brine and dried (Na₂SO₄). Solvent removal provided 1-3 as an oil.

¹H NMR (300 MHz, CDCl₃) δ 1.0-1.15 (2H, m), 1.30-1.70 (16H, m), 2.68 (2H, dt), 3.05 (2H, m), 3.72 (3H, s), 3.91 (2H, t), 4.08 (2H, d), 4.61 (1H, m), 5.10 (2H, m), 5.18 (1H, m), 6.79 (2H, d), 6.98 (2H, d), 7.35 (5H, m).

EXAMPLE 3

Methyl 2-S-Amino-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-4)


To 1-3 (5.0 g, 8.79 mmole) dissolved in absolute ethanol (150 mL) was added 10% Pd/C (0.5 g) and the

resulting suspension was hydrogenated under balloon pressure for 12 hours. The catalyst was then filtered off and the solvent was removed in vacuo to give 1-4 (3.6 g) as an oil.

¹H NMR (300 MHz, CDCl₃) δ 1.00-1.20 (2H, m), 1.22-1.55 (12H, m), 1.60-1.75 (4H, m), 2.00 (2H, bs), 2.68 (2H, t), 2.87 (1H, dd), 3.05 (1H, dd), 3.72 (3H, s), 3.93 (2H, t), 4.09 (2H, m), 6.82 (2H, d), 7.10 (2H, d).

5

EXAMPLE 4


25 Methyl 2-S-(n-Butylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-8)

1-4 (0.59 g, 1.36 mmole) was dissolved in ethyl acetate (10 mL) and NaHCO₃ (0.7 g, 8.68 mmole) was added with stirring at room temperature followed by butanesulfonyl chloride (0.36 mL, 2.76 mmole) and the resulting mixture was refluxed for 26 hours. The cooled reaction mixture was filtered and concentrated and the residue was purified by flash chromatography on silica gel eluting with 4:1 hexane/EtOAc to give pure 1-8 (0.305 g) R_f = 0.7 in 1:1 hexane/EtOAc, ninhydrin stain.

30 ¹H NMR (300 MHz, CDCl₃) δ 0.82 (3H, t), 1.05 (2H, dd), 1.45 (9H, s), 1.1-1.6 (1H, m), 1.7 (4H, m), 2.6 (2H, t), 2.6-2.8 (2H, m), 2.78 (1H, dd), 3.05 (1H, dd), 3.7 (3H, s), 3.93 (2H, t), 4.05 (2H, dd), 4.15 (1H, dd), 6.85 (2H, d), 7.15 (2H, d).

35

EXAMPLE 5

2-S-(n-Butylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride (1-9)

55 1-8 (0.325 g, 0.59 mmole) was dissolved in 1:1:1 CH₃OH/H₂O/THF and LiOH•H₂O (0.157 g, 3.76 mmole) was added. The resulting solution was stirred at room temperature for 3 hours, then concentrated, diluted with 10% KHSO₄ and extracted with EtOAc. This provided 2-S-(n-butylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid. This acid (0.315 g, 0.59 mmole) was dissolved in EtOAc (20 mL) and treated with HCl gas at -20° C for 15 minutes. The reaction mixture was then stoppered and was stirred

at -5°C for 1 hour at which time all starting material was consumed. Argon gas was bubbled through the reaction mixture for 15 minutes and the solvent was removed to give a residue that was triturated with ether to provide pure 1-9 (0.29 g) as a pale yellow solid.


5 ^1H NMR (300 MHz, CD_3OD) δ 0.85 (3H, t), 1.2 (2H, dd), 1.2-1.7 (9H, m), 1.7 (2H, m), 1.95 (2H, bs), 2.65 (2H, t), 2.8 (1H, dd), 2.95 (2H, bt), 3.10 (1H, dd), 3.83 (2H, bs), 3.95 (2H, t), 4.1 (1H, dd), 6.85 (2H, d), 7.2 (2H, d).

Analysis for $\text{C}_{22}\text{H}_{38}\text{N}_2\text{O}_5\text{S} \bullet \text{HCl} \bullet 0.8\text{H}_2\text{O}$

Calculated: C = 53.76, H = 7.92, N = 5.70

Found: C = 53.76, H = 7.66, N = 5.44.

10 EXAMPLE 6




Methyl 2-S-(Benzylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-10)

1-4 (0.59g, 1.36 mmole) was treated with benzylsulfonyl chloride (0.263 g, 1.38 mmole) as described above for 1-8. The crude reaction product was purified by flash chromatography on silica gel eluting with 3:1

30 hexane/EtOAc to give pure 1-10 (0.35 g) as an oil.

1-10 (0.35 g), ^1H NMR (300 MHz, CD_3OD) δ 0.85-1.10 (2H, m), 1.10-1.23 (2H, m), 1.35-1.52 (11H, m), 1.61-1.80 (4H, m), 2.65-3.00 (4H, m), 3.65 (3H, s), 3.90-4.14 (5H, m), 6.85 (2H, d), 7.08 (2H, d), 7.22 (2H, m), 7.30 (3H, m).

EXAMPLE 7



50 2-S-(Benzylsulfonylamino)-3-[4-(piperidin-4-yl)butyl-oxyphenyl]propionic acid hydrochloride (1-11)


Treatment of 1-10 (0.354 g, 0.60 mmole) with LiOH (0.15 g, 3.7 mmole) as described for 1-8 gave 2-S-(benzylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid (0.35 g) as a viscous oil.

55 ^1H NMR (300MHz CD_3OD) δ 0.84-1.06 (3H, m), 1.23 (4H, m), 1.34-1.50 (11H, m), 1.60-1.78 (5H, m), 2.65 (2H, bt), 2.82 (1H, m), 3.02 (1H, m), 3.91 (2H, m), 3.96-4.12 (5H, m), 6.83 (2H, d), 7.15 (2H, d), 7.22 (2H, m), 7.29 (3H, m).

This acid (0.35 g, 0.60 mmole) was dissolved in 20 mL EtOAc and treated with HCl gas as described for

1-9 to give pure 1-11 as a white solid (0.30 g).

¹H NMR (300MHz, CD₃OD) δ 1.32 (4H, m), 1.40-1.65 (3H, m), 1.72 (2H, m), 1.92 (2H, d), 2.77-3.08 (4H, m), 3.33 (3H, m), 3.95-4.14 (5H, m), 6.86 (2H, d), 7.17 (2H, d), 7.28 (2H, m), 7.31 (3H, m).



Methyl 2-S-(2-Styrylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-12)

1-4 (0.647 g, 15 mmoles) was dissolved in ethyl acetate (20 ml), and NaHCO₃ (0.454 g, 5.4 mmoles) was added followed by β -styrenesulfonyl chloride (0.365 g, 18.0 mmoles) and the resulting reaction mixture was heated at reflux with stirring for 16 hours. The cooled reaction mixture was filtered, the solvent removed and the residue was purified by flash chromatography on silica gel eluting with hexane (3)/ethyl acetate (1) to give pure 1-12.

¹H NMR (300 MHz, CDCl₃) δ 1.10 (2H, m), 1.30-1.55 (14 H, m), 1.65-1.80 (4H, m), 2.68 (2H, t), 3.01 (2H, dt), 3.62 (3H, s), 3.88 (2H, t), 4.09 (2H, m), 4.22 (1H, m), 4.98 (1H, d), 6.45 (1H, d), 6.80 (2H, d), 7.06 (2H, d), 7.40 (4H, s).


30 2-S-(2-Styrylsulfonylamino)-3-[4-piperidinylbutyloxyphenyl]propionic acid hydrochloride (1-13)

1-12 (0.58 g, 0.97 mmole) was dissolved in THF(1)-H₂O(1)-MeOH(1) (15 ml) and lithium hydroxide (0.12 g, 5.0 mmole) was added and the resulting clear solution was stirred overnight at room temperature.

The reaction mixture was diluted with 75 ml H₂O, acidified to pH 2-3 with 10% KHSO₄ solution and then extracted with 3 x 50 ml EtOAc. The organic extract was dried, the solvent removed, and the residue purified by flash chromatography on silica gel eluting with CHCl₃(97)-MeOH(3)-HOAc(1) to give the desired acid (R_f=0.2).

This acid was dissolved in EtOAc and treated with HCl gas as described for 1-9 to give 1-13.

¹H NMR (300 MHz, CD₃OD) δ 1.15-1.70 (10H, m), 1.70-1.82 (2H, t), 1.97 (2H, t), 2.78-3.12 (5H, m), 3.35 (3H, m), 3.87 (2H, t), 4.03 (1H, m), 6.50 (1H, d), 6.69 (2H, m), 7.18 (3H, m), 7.41 (5H, bs).



2-S-(2-Phenethylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionic acid (1-14)

1-12a (0.21 g) was dissolved in 20 ml absolute ethanol, 0.1 g 10% Pd/C was added and the stirred sus-


pension was hydrogenated under balloon pressure. After 4 hours the reaction was stopped and the solvent was removed to give the desired product 1-14 (0.194 g).

⁵ ¹H NMR (300 MHz, CD₃OD) δ 1.05 (2H, m), 1.30-1.40 (3H, m), 1.47 (14H, m), 1.72 (5H, m), 2.67-2.93 (8H, m), 3.13 (1H, m), 3.31 (2H, m), 3.82 (2H, m), 4.00-4.20 (4H, m), 6.82 (2H, d), 7.07 (2H, d), 7.21 (5H, m).

¹⁰ 2-S-(2-Phenethylsulfonylamino)-3-4-[4-piperidinylbutyloxyphenyl]propionic acid hydrochloride (1-15)

¹⁵ 1-14 (0.194 g) was dissolved in EtOAc and treated with HCl gas as described for 1-9 to provide pure 1-15 (0.145 g).

²⁰ ¹H NMR (300 MHz, CD₃OD) δ 1.25-1.68 (8H, m), 1.73 (2H, m), 1.93 (2H, m), 2.78 (3H, m), 2.91 (4H, m), 3.13 (1H, m), 3.33 (4H, m), 3.86 (2H, m), 4.18 (1H, m), 6.80 (2H, d), 7.09 (2H, d), 7.22 (5H, m).



Methyl 2-S-(Phenylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate (1-16).

³⁰ 1-4 (0.647 g, 1.5 mmoles) was treated with phenylsulfonyl chloride (0.318 g, 1.8 mmoles) as described for 1-8. The crude product was purified by flash chromatography on silica gel eluting with CHCl₃(98)-MeOH(2) to give pure 1-16 (0.67 g).


³⁵ ¹H NMR (300 MHz, CDCl₃) δ 1.09 (2H, m), 1.25-1.40 (3H, m), 1.42 (9H, bs), 1.60-1.85 (6H, m), 2.66 (2H, m), 2.96 (2H, d), 3.55 (3H, s), 3.89 (2H, t), 4.09 (4H, m), 5.12 (1H, d), 6.72 (2H, d), 6.95 (2H, d), 7.40-7.65 (3H, m), 7.75 (2H, m).

⁴⁰ 2-S-(Phenylsulfonylamino)-3-(4-piperidin-4-ylbutyloxyphenyl)propionic acid hydrochloride (1-17).

⁴⁵ 1-16 (0.525 g) was treated with lithium hydroxide as described for 1-8 to give crude product that was purified by flash chromatography on silica gel eluting with CHCl₃(97)-MeOH(3)-HOAc(1) to provide pure acid (R_f = 0.2).

This acid was treated with HCl gas in EtOAc as described for 1-9 to provide pure 1-17.

⁵⁰ ¹H NMR (300 MHz, CD₃OD) δ 1.28-1.47 (6H, m), 1.50-1.70 (3H, m), 1.75 (2H, m), 1.97 (2H, d), 2.77 (1H, m), 2.95 (3H, m), 3.35 (4H, m), 3.93 (3H, m), 6.72 (2H, d), 7.02 (2H, d), 7.41 (2H, m), 7.52 (1H, m), 7.67 (2H, m).



Methyl 2-S-(2-Thienylsulfonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]propionate

(1-18).

1-4 (0.304 g, 0.7 mmoles) was treated with 2-thienylsulfonyl chloride (0.155 g, 0.85 mmoles) as described for 1-8 to provide crude product. This was purified by flash chromatography on silica gel eluting with CHCl_3 (98)- CH_3OH (2) to afford pure 1-18 as a viscous oil, R_f 0.3 [silica gel, CHCl_3 (98)- CH_3OH (2)]

5 ^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.31 (4H, m), 1.36-1.80 (16H, m), 2.68 (2H, bt), 3.03 (2H, d), 3.57 (3H, s), 3.91 (2H, t), 4.08 (2H, m), 4.29 (1H, m), 5.16 (1H, d), 6.78 (2H, d), 7.00 (4H, m), 7.55 (2H, dd).

2-S-(2-Thienylsulfonylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride (1-19).

10 Treatment of 1-18 (0.22 g, 0.38 mmoles) with LiOH (0.045 g, 1.89 mmoles) as described for 1-8 provided the desired acid, which was purified by flash chromatography on silica gel eluting with CHCl_3 (97)- CH_3OH (3)- HOAc (1).

15 ^1H NMR (300 MHz, CD_3OD) δ 1.05 (2H, d t), 1.20-1.40 (5H, m), 1.40-1.60 (12H, m), 1.65-1.80 (5H, m), 2.65-2.82 (4H, m), 2.98 (1H, dd), 3.30 (1H, m), 3.92 (2H, t), 4.00-4.13 (5H, m), 6.75 (2H, d), 7.02 (3H, m), 7.39 (1H, d), 7.67 (1H, d).


Treatment of this acid with HCl gas as described for 1-9 provided 1-19 as a white solid after trituration.

Analysis Calcd. for $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_5\text{S}_2 \bullet \text{HCl} \bullet 0.5 \text{ H}_2\text{O}$:

20 **C, 51.60, H, 6.30, N, 5.47.**

Found: C, 51.57, H, 6.20, N, 5.51.

25 ^1H NMR (300 MHz, CD_3OD) δ 1.29-1.45 (4H, m), 1.47-1.70 (3H, m), 1.71-1.83 (2H, m), 1.91-2.00 (2H, bd), 2.79 (1H, m), 2.90-3.04 (3H, m), 3.95 (2H, t), 4.04 (1H, m), 6.76 (2H, d), 7.05 (3H, m), 7.40 (1H, m), 7.79 (1H, m).



1-4 (0.304 g, 0.7 mmoles) was treated with dansyl chloride (0.208 g, 0.77 mmoles) as described for 1-8 to provide crude product which was purified by flash chromatography on silica gel eluting with hexane(75)- EtOAc (25) to give pure 1-20. R_f 0.25 (silica gel eluting with hexane(75)- EtOAc (25)).

50 ^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.21-1.38 (6H, m), 1.40-1.53 (11H, m), 1.60-1.80 (6H, m), 2.68 (2H, bt), 2.89 (6H, s), 3.33 (2H, s), 3.89 (2H, t), 4.05-4.19 (4H, m), 5.24 (1H, m), 6.62 (2H, d), 6.82 (2H, d), 7.18 (1H, d), 7.50 (2H, m), 8.19 (2H, t), 8.51 (1H, d).

55 **2-S-(Dansylamino)-3-[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride (1-21).**

Treatment of 1-20 (0.275 g, 0.412 mmoles) with LiOH as described for 1-8 gave the desired acid as a highly fluorescent viscous residue.

¹H NMR (300 MHz, CD₃OD) δ 1.09 (2H, m), 1.22-1.40 (3H, m), 1.40-1.57 (12H, m), 1.65-1.80 (3H, m), 2.60-2.80 (3H, m), 2.90 (6H, s), 3.31 (3H, m), 3.80 (2H, t), 3.90 (1H, m), 4.01-4.15 (4H, m), 6.47 (2H, d), 7.21 (1H, d), 7.42 (2H, m), 7.98 (1H, d), 8.20 (1H, d), 8.46 (1H, d).

5 Treatment of this acid in EtOAc with HCl gas as described for 1-9 provided 1-21 as a white solid upon ethylacetate trituration.

Analysis for C₃₀H₃₉N₃O₅S•1.8 HCl•H₂O:

10 C, 56.53; H, 6.77; N, 6.59; Cl, 10.01.

Found: C, 56.48; H, 6.66; N, 6.36; Cl, 10.21.

15 ¹H NMR (300 MHz, CD₃OD) δ 1.30-1.51 (7H, m), 1.52-1.80 (4H, m), 1.95 (2H, bt), 2.65 (1H, m), 2.95 (3H, m), 3.30-3.40 (4H, m), 3.45 (6H, s), 3.84-3.97 (3H, m), 6.45 (2H, d), 6.77 (2H, d), 7.71 (2H, m), 8.00 (1H, d), 8.16 (2H, d), 8.55 (1H, d), 8.70 (1H, d).

20

25

30

35


40

45

50

55

SCHEME 2



5

10

15

20

25

30

35


40

45

50

55

EXAMPLE 8


2-S-(Benzylxycarbonylamino)-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionic acid (2-1)

15 N-CBZ-L-tyrosine (15.0 g, 0.045 mole) was dissolved in 75 mL DMF and added at 0-10° C to a suspension of sodium hydride (2.16 g, 0.09 mole) in 25 mL DMF. The resulting suspension was stirred at 0-10° C for 1.0 hour and then 6-(t-butyloxycarbonylamino)hexyl bromide (12.6 g, 0.045 mole) in 25 mL DMF was added dropwise at 0-5° C and the clear, dark reaction mixture was stirred at room temperature overnight.

20 After solvent removal, the residue was taken up in EtOAc and this was made acidic with 10% KHSO₄ solution. The organic phase was separated, washed with brine, dried (Na₂SO₄) and the solvent removed to give an oil. This was purified by column chromatography on silica gel eluting with 98:2:1 CHCl₃/CH₃OH/HOAc to give pure 2-1 as a clear oil.

¹H NMR (300 MHz, CD₃OD) δ 1.45 (1H, m), 1.75 (2H, m), 2.80-3.15 (6H, m), 3.91 (2H, t), 4.38 (1H, m), 4.95 (6H, m), 6.85 (2H, d), 7.06 (2H, d)


25 EXAMPLE 9

Methyl 2-S-(Benzylxycarbonylamino)-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionate (2-2)

35 Compound 2-1 (10.0 g, 19.43 mmole) in 75 mL DMF was treated with cesium carbonate (3.16 g, 9.72 mmole) with stirring at room temperature for 1.9 hours. Then, methyl iodide (2.76 g, 19.43 mmole) was added dropwise and the reaction mixture was stirred overnight at ambient temperature. The solvent was removed at high vacuum (30° C) and the residue was taken up in 300 mL EtOAc and washed with 2 x 40 mL portions of saturated NaHCO₃ solution, brine and dried (Na₂SO₄). Solvent removal provided 2-2 (8.5 g, 83%) as a clear oil.

¹H NMR (300MHz, CDCl₃) δ 1.25-1.53 (16H, m), 1.76 (2H, m), 2.96-3.17 (4H, m), 3.71 (3H, s), 3.90 (2H, t), 4.61 (1H, m), 5.10 (2H, m), 5.19 (1H, m), 6.88 (2H, d), 6.98 (2H, d), 7.32 (5H, m).

EXAMPLE 10

Methyl 2-Amino-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionate (2-3)

55 Compound 2-2 (8.0 g, 15.1 mmole) was dissolved in 150 mL absolute ethanol and 1.0 g 10% Pd/ C was added. This suspension was hydrogenated in a Parr apparatus (50 psi) for 3.5 hours. The catalyst was then filtered off and the solvent removed on the rotary evaporator to give pure 2-3 (5.56 g) as a clear oil. R_f = 0.4 on SiO₂ with 95:5 CHCl₃/CH₃OH


¹H NMR (300 MHz, CDCl₃) δ 1.30-1.55 (16H, m), 1.70 (2H, m), 2.80 (1H, m), 3.00-3.17 (3H, m), 3.71 (3H, s),

3.93 (2H, t), 6.82 (2H, d), 7.09 (2H, d).

EXAMPLE 11

5

10




15

2-S-(Methylsulfonylamino)-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionate (2-4)

2-3 (0.40 g, 1.01 mmole) was treated with methanesulfonyl chloride (0.116 g, 1.01 mmole) and NaHCO_3 (0.25 g, 3.0 mmole) as described for 1-8. The crude reaction product was purified by flash chromatography on silica gel eluting with 30% EtOAc/hexanes to give pure 2-4 (0.10g) as a clear oil.
 $^1\text{H NMR}$ (300MHz, CDCl_3) δ 1.36-1.56 (1H, m), 1.77 (2H, m), 2.70 (3H, s), 3.78 (3H, s), 3.92 (2H, t), 4.36 (1H, m), 4.90 (1H, d), 6.82 (2H, d), 7.09 (2H, d).

20 EXAMPLE 12

25

2-S-(Methylsulfonylamino)-3-[4-(6-aminohexyloxy)phenyl]propionic acid hydrochloride (2-5)

30 2-4 (0.1 g, 0.212 mmole) was treated with LiOH (0.026 g, 1.06 mmole) as described for 1-8 to provide 2-S-(methylsulfonylamino)-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionic acid (0.125g) as a viscous oil.

$^1\text{H NMR}$ (300 MHz, CD_3OD) δ 1.30-1.55 (1H, m), 1.75 (2H, m), 2.63 (3H, s), 2.85 (1H, dd), 3.0-3.13 (3H, m), 3.93 (2H, t), 4.17 (1H, m), 6.83 (2H, d), 7.20 (2H, d).

35 This acid was dissolved in EtOAc (20 mL) and treated with HCl gas as described for 1-9. Solvent removal provided a residue that was triturated with 30 mL Et_2O to provide pure 2-5 as a white solid (0.09 g).

$^1\text{H NMR}$ (300MHz, CD_3OD), δ 1.40-1.60 (4H, m), 1.60 (2H, m), 1.69 (2H, m), 2.68 (3H, s), 2.82 (1H, dd), 2.92 (2H, t), 3.10 (1H, dd), 3.30 (2H, m), 3.97 (2H, t), 4.18 (1H, m), 6.83 (2H, d), 7.19 (2H, d).

Analysis for $\text{C}_{18}\text{H}_{28}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}\cdot 0.25\text{ H}_2\text{O}$


40 Calculated: C = 48.11, H = 6.94, N = 7.01

Found: C = 48.16, H = 6.82, N = 6.98.

EXAMPLE 13

45


50

Methyl 2-S-(Butylsulfonylamino)-3-[4-(6-N-t-butyloxycarbonylaminohexyloxy)phenyl]propionate (2-6)

55 2-3 (0.40 g, 1.01 mmole) was treated with butylsulfonyl chloride (0.47 g, 3.03 mmole) and NaHCO_3 (0.50 g, 6.0 mmole) as described for 1-8. Crude reaction product was purified by flash chromatography on silica gel eluting with 30% EtOAc/hexanes to give pure 2-6 (0.22 g) as a clear oil.

$^1\text{H NMR}$ (300MHz, CDCl_3) δ 0.87 (3H, t), 1.35-1.54 (18 H, m), 1.61 (2H, m), 1.77 (2H, m), 2.74 (2H, t), 2.95 (1H, dd), 3.05-3.18 (3H, m), 3.90 (2H, t), 4.32 (1H, m), 4.72 (1H, m), 6.82 (2H, d), 7.07 (2H, d).

EXAMPLE 14

2-S-(Butylsulfonylamino)-3-[4-(6-aminohexyloxy)phenyl]propionic acid hydrochloride (2-7)

2-6 (0.2 g, 0.39 mmole) was treated in THF (1)/H₂O (1)/CH₃OH (1) solution with LiOH (0.05g, 2.12 mmole) as described for 1-8 to provide 2-S-(butylsulfonylamino)-3-[4-(6-N-t-butyloxycarbonylaminoxyloxy)phenyl]propionic acid (0.235 g) as a viscous oil.

16 ¹H NMR (300 MHz, CD₃OD) δ 0.83 (3H, t), 1.35-1.56 (16H, m) 1.76 (2H, m), 2.61 (2H, t), 2.79 (1H, ddd), 3.00-3.14 (3H, m), 3.92 (2H, t), 4.11 (1H, m), 6.82 (2H, d), 7.18 (2H, d).

This acid (0.235 g, 0.7 mmole) was dissolved in EtOAc (30 mL) and treated with HCl gas as described for 1-9. The residue was triturated with a solution of ether (40 mL)/EtOAc (10mL) to provide 2-7 (0.17g) as a white solid.


17 ¹H NMR (300MHz, CD₃OD) δ 0.85 (3H, t), 1.24 (2H, m), 1.35-1.60 (6H, m), 1.70 (2H, m), 1.80 (2H, m), 2.66 (2H, t), 2.78 (1H, dd), 2.92 (2H, t), 3.10 (1H, dd), 3.30 (1H, m), 6.85 (2H, d), 7.20 (2H, d).

18 Analysis for C₁₉H₃₂N₂O₅S.HCl

19 Calculated: C = 52.22, H = 7.61, N = 6.41

20 Found: C = 51.80, H = 7.61, N = 6.33.


EXAMPLE 14A

30 2-S-(Butylsulfonylamino)-3-[4-(6-acetamidohexyloxy)phenyl]propionic acid (2-7a)


A solution of 2-7 (1.0 g, 2.29 mmole) in THF (30 ml) is treated with ethyl acetimidate (0.2 g, 2.29 mmol) and the resulting reaction mixture is stirred at room temperature for 16 hours. The solvent is then removed and the residue is recrystallized from ethyl acetate to give pure 2-7a.

50

55


EXAMPLE 14B2-S-(Butylsulfonylamino)-3-[4-(6-benzamidinohexyloxy)phenyl]propionic acid (2-7b)

20 A solution of 2-7 (1.0 g, 2.29 mmole) in THF (30 ml) is treated with ethyl benzimidate (0.34 g, 2.29 mmole) and the resulting solution is stirred at room temperature for 20 hrs. The solvent is removed and the residue is taken up in EtOAc, filtered and recrystallized to give pure 2-7b.

EXAMPLE 14C2-S-(Butylsulfonylamino)-3-[4-(6-guanidinohexyloxyphenyl]propionic acid (2-7c)

40 A mixture of 2-7 (1.0 g, 2.29 mmol) and N-nitrosomethylthiouguanidine (0.32 g, 2.29 mmol) is heated at 40° for 5 minutes in absolute EtOH (15 ml) and then is allowed to stand for 1 day at room temperature. The solvent is removed in vacuo and the residue is purified by flash chromatography on silica eluting with CHCl₃(95)-CH₃OH(5)-HOAc(2) to give the desired nitroguanidino intermediate.

45 This is dissolved in 10% HCl-CH₃OH (20 ml) and shaken in a Parr apparatus (50 psi) in the presence of 10% Pd-C (100 mg) at room temperature for 8 hours. The catalyst is then removed by filtration, the solvent is removed in vacuo, and the residue dissolved in 10% aqueous HCl solution and heated at reflux for 2 hours. The solvent is removed in vacuo and the residue purified by chromatography on a Dowex 1-X2 column eluting with water to give pure 2-7c.

EXAMPLE 15

Methyl 2-S-(Benzylsulfonylamino)-3-[4-(6-N-t-butylcarboxyaminohexyloxy)phenyl]propionate (2-8)

2-3 (0.29 g, 0.735 mmole) was treated with benzylsulfonyl chloride (0.14 g, 0.735 mmole) and NaHCO₃ (0.185 g, 2.2 mmole) as described for 1-8. The crude reaction product was purified by flash chromatography


5 on silica gel eluting with 1:1 hexanes/EtOAc to give pure 2-8 (0.27 g) as a clear oil.

¹H NMR (300 MHz, CDCl₃) δ 1.47-1.69 (15H, m), 1.90 (2H, m), 2.18 (2H, s), 3.08 (2H, d), 3.25 (2H, m), 3.85 (3H, s), 4.05 (2H, t), 4.19-4.20 (4H, m), 4.80 (1H, d), 6.83 (2H, d), 7.12 (2H, d), 7.47 (5H, m).

EXAMPLE 16

10

15



20

2-S-(Benzylsulfonylamino)-3-[4-(6-aminohexyloxy)phenyl]propionic acid hydrochloride (2-9)

2-8 (0.48 g, 0.875 mmole) was treated with LiOH (0.105 g, 4.37 mmole) as described for 1-8 to give 2-S-(benzylsulfonylamino)-3-[4-(6-N-t-butylcarboxyaminohexyloxy)phenyl]propionic acid (0.4 g) as a foam.

25 ¹H NMR (300 MHz, CD₃OD) δ 1.30-1.52 (15H, m), 1.72 (2H, m), 2.81 (1H, dd), 3.00 (3H, m), 3.93 (2H, m), 4.06 (2H, m), 6.81 (2H, d), 7.13 (2H, d), 7.20-7.32 (5H, m).


This acid (0.4g, 0.75 mmole) was dissolved in EtOAc (30 mL) and treated with HCl gas as described for 1-9. Crude reaction product was triturated with ether to give pure 2-9 (0.35 g) as a white solid.

20 ¹H NMR (300 MHz, CD₃OD) δ 1.38-1.57 (4H, m), 1.65 (2H, m), 1.73 (2H, m), 2.71 (1H, dd), 2.89 (2H, t), 3.02 (1H, dd), 3.30 (3H, m), 3.94-4.15 (5H, m), 6.83 (2H, d), 7.15 (2H, d), 7.29 (5H, m).


30

EXAMPLE 16 A

35



40



45


2-S-(Benzylsulfonylamino)-3-[4-(6-(acetamidinohexyloxy)phenyl]propionic acid (2-9a)

A solution of 2-9 (1.0 g, 2.1 mmol) in THF (30 ml) is treated with ethyl acetimidate (0.18 g, 2.1 mmol) as described in Example 14A to give pure 2-9a after recrystallization from ethyl acetate.

50

55


EXAMPLE 16 B



15 2-S-(Benzylsulfonylamino)-3-[4-(6-(guanidinoxyhexyloxy)phenyl]propionic acid (2-9b)

A mixture of **2-9** (1.0 g, 2.1 mmol) and N-nitrosomethylthiouguanidine (0.29 g, 2.1 mmol) is treated as described for Example 14C to give pure **2-9b**.

20 SCHEME 3



55 Methyl 2-S-amino-3-[4-(4-hydroxyphenyl)oxyphenyl]propionate (3-2).

CH_3OH (100 ml) was cooled to 0° and treated with SOCl_2 (47 mmol) with stirring for 15 minutes at 0° and then 3-1 (1.5 g, 5.49 mmol) was added with stirring for 16 hours as the temperature rose to ambient.

The reaction mixture was filtered and the solvent was removed to give an oil that provided 3-2 (1.57 g) after ether washing.

¹H NMR (300 MHz, CD₃OD) δ 3.10-3.30 (2H, m), 3.81 (3H, s), 6.76-6.90 (6H, m), 7.20 (2H, d).

5 Methyl 2-S-(N-Benzylloxycarbonylamino)-3-[4-(4-hydroxyphenyl)oxyphenyl]propionate (3-3).

10 A water(1)-dioxane(1) solution (10 ml) of 3-2 (0.2 g, 0.62 mmol) was cooled to 0°C and treated with Na₂CO₃ (0.131 g, 1.23 mmole) and benzylchloroformate (0.619 mmol). After 1.5 hours of vigorous stirring, the dioxane was removed at low pressure and the residue diluted with H₂O and extracted with EtOAc. The organic extract was washed with brine, dried (Na₂SO₄) and the solvent removed to provide 3-3 as an oil.

¹H NMR (300 MHz, CDCl₃) δ 3.06 (2H, m), 3.75 (3H, s), 4.64 (1H, m), 5.10 (2H, m), 5.36 (1H, m), 6.83 (6H, m), 7.00 (2H, d), 7.37 (5H, bs).

15 Methyl-2-S-(N-Benzylloxycarbonylamino)-3-[4-(4-N-t-butyloxycarbonylpiperidin-4-yl)oxyphenyloxy]phenylpropionate (3-4).

20 A benzene (40 ml) solution of 3-3 (0.5 g, 1.18 mmol) was treated with N-t-butyloxycarbonylpiperidin-4-ol (0.24 g, 1.18 mmol) and Ph₃P (0.310 g, 1.18 mmol) while stirring at room temperature with constant N₂ purging. Diethyl azodicarboxylate (1.18 mmol) was added and the resulting solution was stirred at room temperature for 16 hours.

The solvent was then removed and the residue was purified by flash chromatography on silica gel eluting with hexane(70)-EtOAc(30) to provide pure 3-4.

¹H NMR (300 MHz, CDCl₃) δ 1.48 (9H, s), 1.80 (2H, m), 1.95 (2H, m), 3.08 (2H, m), 3.36 (2H, m), 3.76 (3H, s), 4.40 (1H, m), 4.63 (1H, m), 5.10 (1H, m), 5.25 (1H, m), 6.80-7.04 (8H, m), 7.36 (5H, bs).

25 Methyl 2-S-(Butylsulfonylamino)-3-[4-(4-N-t-butyloxycarbonylpiperidin-4-yl)oxyphenyloxy]phenylpropionate (3-5).

30 A solution of 3-4 (0.5 g, 0.082 mmol) in EtOH (40 ml) was treated with 10% Pd/C (125 mg) and this suspension hydrogenated in a Parr flask at 50 psi for 1.5 hour. The catalyst was filtered off and the solvent removed to give the desired amino ester as a clear oil.

¹H NMR (300 MHz, CDCl₃) δ 1.48 (9H, s), 1.50-1.80 (8H, m), 1.91 (2H, m), 2.82 (1H, m), 3.04 (1H, m), 3.34 (2H, m), 3.76 (3H, s), 4.20 (1H, m), 7.90 (8H, m), 8.11 (2H, d).

35 This amino ester (0.36 g, 0.77 mmol) was dissolved in EtOAc (10 ml) and treated with NaHCO₃ (0.386 g, 4.6 mmol) and n-butylsulfonylchloride (1.53 mmol) with heating at reflux for 48 hours. The solvent was removed and the residue purified by flash chromatography on silica gel eluting with hexane(65)-EtOAc(35) to provide pure 3-5 as an oil.

40 ¹H NMR (300 MHz, CDCl₃) δ 0.88-1.02 (4H, m), 1.25-1.45 (3H, m), 1.50 (9H, s), 1.51-1.80 (2H, m), 1.93 (2H, m), 2.80 (2H, m), 2.95-3.20 (2H, m), 3.21-3.40 (2H, m), 3.72 (2H, m), 3.74 (3H, s), 4.38 (2H, m), 4.80 (1H, d), 6.90 (6H, m), 7.10-7.27 (2H, m).

2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)oxyphenyloxy]phenylpropionic acid hydrochloride (3-6).


45 A solution of 3-5 (0.2 g, 0.34 mmol) in THF(1)-H₂O(1)-CH₃OH(1) was treated with LiOH (0.075 g, 1.78 mmol) at room temperature for 8 hours. The solvent was removed and the residue was acidified with 10% KHSO₄ solution and this extracted several times with EtOAc. The organic extracts were combined, washed with brine, dried (Na₂SO₄) and the solvent removed to give the desired acid. R_f = 0.3 [silica gel, 97(CHCl₃)-3(CH₃OH)-1(HOAc)].

50 ¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, t), 1.20-1.30 (3H, m), 1.46 (9H, s), 1.50-2.0 (6H, m), 2.75 (2H, m), 2.97 (1H, m), 3.18 (1H, m), 3.33 (2H, m), 3.76 (2H, m), 4.35 (2H, m), 5.07 (1H, m), 6.89 (6H, m), 7.13 (2H, m).

55 This acid (0.15 g, 0.26 mmol) was dissolved in EtOAc and treated with HCl gas as described for 1-9 to give pure 3-6 as a white solid.

¹H NMR (300 MHz, CD₃OD) δ 0.89 (3H, t), 1.32 (2H, m), 1.53 (2H, m), 1.97-2.21 (4H, m), 2.75 (2H, m), 2.63 (1H, m), 3.20 (3H, m), 3.40 (2H, m), 4.14 (1H, m), 6.82-7.05 (6H, m), 7.23 (2H, m).

SCHEME 4



4[4-(N-Benzylloxycarbonylpiperidin-4-yl)-2-methyl]pentan-2-ol(4-2).

35 Methyl 4-(N-Benzylloxycarbonylpiperidin-4-yl)butanoate (4-1) (10.07 g, 0.032 mol) in THF (200 ml) was cooled to 0°C and treated with CH_3MgI (0.095 mol) for 3.0 hours. The reaction mixture was poured into ice, acidified with 10% KHSO_4 and extracted with 3 portions of EtOAc . The combined organic extract was washed with brine, dried (MgSO_4) and the solvent removed. The residue was purified by flash chromatography on silica gel eluting with hexane(7)- EtOAc (3) to give pure 4-2. R_f = 0.3 (silica gel, hexane (7)- EtOAc (3)).

Methyl 2-S-(Butylsulfonylamino)-3-[4-(N-Benzylloxycarbonylpiperidin-4-yl)-2,2-dimethyl]butyloxyphenyl-propionate (4-3).

45 N-n-Butylsulfonyl-L-tyrosine methyl ester (7.21 g, 0.023 mole) was dissolved in a mixture of 4-2(1.0g),
 CH₂Cl₂ (30 ml) and benzene (250 ml). Triphenylphosphine (5.97 g, 0.023 mole) was added and after purging
 with N₂, diethyl azodicarboxylate (3.6 ml, 0.023 mole) was added at room temperature as the reaction mixture
 turned red-orange in color. Reaction mixture stirred at room temperature for 7 days. Solvent was removed and
 the residue was purified by flash chromatography on silica gel eluting with hexane(60)-EtOAc(40) to give pure
 50 4-3

1H NMR (300 MHz, CDCl₃) δ 0.88 (6H, t), 1.10-1.40 (12H, m), 1.43-1.78 (8H, m), 2.70-2.82 (4H, m), 2.95-3.10 (3H, m), 3.75 (3H, s), 4.18 (2H, m), 4.32 (1H, m), 5.13 (2H, s), 6.88 (2H, d), 7.06 (2H, d), 7.38 (5H, m).

2-S-(Butylsulfonylamino)-3-[4-(N-Benzylloxycarbonylpiperidin-4-yl)-2,2-dimethyl]butyloxyphenylpropionic acid (4-4).

Dissolved 4-3 (0.64 g, 0.001 mole) in THF/H₂O/CH₃OH mixture and treated with LiOH (0.26 g, 0.0062 mole) at room temperature for 8 hours. Solvent removal, acidification (KHSO₄ solution) and EtOAc extraction provided

crude 4-4 which was purified by flash chromatography on silica gel eluting with CHCl_3 (97)- CH_3OH (3)- HOAc (1) to give pure 4-4.

^1H NMR (300 MHz, CDCl_3) δ 0.86 (6H, s), 1.05-1.50 (13H, m), 1.55-1.80 (5H, m), 2.77 (4H, m), 3.04 (2H, m), 4.10 (2H, bd), 4.17 (1H, m), 4.85 (1H, d), 5.14 (2H, s), 6.88 (2H, d), 7.13 (2H, d), 7.39 (5H, m).

5


2-S-(Butylsulfonylamino)-3-[4-(piperidin-4-yl)-2,2-dimethyl]butyloxyphenylpropionic acid (4-5).


To ammonium formate (0.23 g, 3.65 mmol) in CH_3OH (5 ml) was added 4-4 (0.22 g, 3.65 mmole) in 10 ml CH_3OH and then 10% Pd/C (100 mg) was added at room temperature. After 15 minutes the reaction mixture was passed thru a Solka Floc pad and the solvent removed. This residue was purified by flash chromatography on silica gel eluting with EtOH (9)- H_2O (1)- NH_4OH (1) to give pure 4-5.

^1H NMR (300 MHz, CD_3OD) δ 0.88 (6H, s), 1.15-1.40 (12H, m), 1.42-1.70 (7H, m) 1.90 (2H, d), 2.78-3.00 (6H, m), 3.06 (1H, dd), 3.35 (3H, m), 3.93 (1H, m), 6.86 (2H, d), 7.20 (2H, d).

15

SCHEME 5






5-1

10 Methyl 3-S-(Benzylxycarbonylamino)-4-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]butyrate (5-1).

15 A solution of compound 1-2 (1.0 g, 1.8 mmole) and N-methylmorpholine (0.21 mL, 1.9 mmole) in EtOAc (10 mL) was stirred at -15°C and treated with isobutyl chloroformate (0.24 mL, 1.8 mmole). After 15 minutes the heterogeneous mixture was treated portion-wise with an ethereal solution of diazomethane (0.5M:10 mL, 5.0 mmole), followed by continued stirring at 0° for 1.0 hour. The reaction mixture was then purged with argon for 10 minutes to remove excess diazomethane. The organic phase was washed with 2 x 5 mL portions of H₂O, brine, dried (MgSO₄), and evaporated. The residue was then dissolved in CH₃OH (15 mL) and treated sequentially with triethylamine (0.7 mL, 5.0 mmole) and AgO₂CPh (110 mg, 0.5 mmole) while stirring at ambient temperature to effect vigorous gas evolution. After 30 minutes the solvent was evaporated and then the crude reaction product purified by flash chromatography on silica gel eluting with 4:1 hexane/EtOAc to give 5-1 (0.52 g) as an oil.

20 TLC R_f = 0.23 (30% EtOAc/hexane)




5-2

30 Methyl 3-S-Amino-4-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]butyrate (5-2).

35 To 5-1 (0.52 g, 0.9 mmole) dissolved in absolute ethanol (20 mL) was added 10% Pd/C (0.25 g) and the resulting suspension was hydrogenated under balloon pressure for 12 hours. The catalyst was then filtered off and the solvent was removed in vacuo to give 5-2 (0.35 g) as an oil.


TLC R_f = 0.15 (9:1:1 CH₂Cl₂/CH₃OH/AcOH).



5-3

45 Methyl 3-S-(Butylsulfonylamino)-4-[4-(N-t-butyloxycarbonylpiperidin-4-yl)butyloxyphenyl]butyrate (5-3).

50 To 5-2 (0.36 g, 0.8 mmole), triethylamine (170 μ L, 1.2 mmole), 4-dimethylaminopyridine (12 mg, 0.1 mmole), and THF (5 mL) at 0°C was added n-butylsulfonyl chloride (130 μ L, 1.0 mmole) with stirring. The cooling bath was removed and stirring was continued for 6 hours. The reaction mixture was diluted with 10 mL of EtOAc and then washed with 2x5 mL H₂O, brine, dried (MgSO₄), and concentrated. The crude reaction product was purified by flash chromatography on silica gel eluting with 4:1 hexane/EtOAc to give 5-3 (180 mg) as an oil. ¹H NMR (300 MHz, CDCl₃) δ 1.12 (2H, m), 1.25-1.83 (13H, m), 1.29 (3H, t), 1.47 (9H, s), 2.68 (6H, m), 2.87 (2H, d), 3.73 (3H, s), 3.93 (2H, t), 4.08 (1H, m), 4.72 (1H, d), 6.87 (2H, d), 7.12 (2H, d).




5 - 4

10 3-S-(Butylsulfonylamino)-4-[4-N-t-butyloxycarbonylpiperidin-4-yl]butyloxyphenyl]butanoic acid (5-4).

15 Compound 5-3 (175 mg, 0.33 mmole) in CH₃OH (4.0 mL) was treated with 1N NaOH (1.0 mL, 1.0 mmole) followed by continued stirring at ambient temperature for 20 hours. The reaction mixture was diluted with 15 mL EtOAc and then washed with 10 mL 5% KHSO₄ and brine, dried (MgSO₄), and concentrated to give 5-4 (160 mg) as an oil.

TLC R_f = 0.31 (9:0.5:0.5 CH₂Cl₂/CH₃OH/AcOH).



5 - 5

25 3-S-(Butylsulfonylamino)-4-[4-piperidin-4-yl]butyloxyphenyl]butanoic acid (5-5)

30 To a stirred solution of compound 5-4 (160 mg, 0.30 mmole), CH₂Cl₂ (2.0 mL), and anisole (100 μ L) at 0°C was added CF₃CO₂H (1.0 mL). After 1.5 hours at 0°C the solvents were evaporated and the crude reaction product purified by flash chromatography on silica gel eluting with 10:0.8:0.8 ethanol/H₂O/conc. NH₄OH to give 5-5 (42 mg) as a solid.

35 ¹H NMR (300 MHz, D₂O/CF₃CO₂D) δ 0.82 (3H, t), 1.10-1.70 (11H, m), 1.80 (m, 2H), 1.98 (m, 2H), 2.48 (2H, t), 2.72 (3H, m), 3.00 (3H, m), 3.43 (2H, m), 3.96 (1H, m), 4.10 (2H, t), 7.01 (2H, d), 7.32 (2H, d).


40

45

50

55

SCHEME 6



35 Methyl 2-S-(N-Benzylloxycarbonylamino)-3-[4-(3-chloropropoxyphenyl)propionate (6-1).

Treatment of a DMF solution of 1-1 (0.95 g, 2.9 mmol) and 3-chloro-1-tosyloxypropane (0.84 g, 3.19 mmol) with cesium carbonate (0.47 g, 1.45 mmole) gave a solution that was stirred at room temperature overnight. The reaction mixture was then diluted with H₂O and extracted with ether. The ether extract was washed with brine, dried (Na₂SO₄) and the solvent removed to give an oily residue. This was purified by flash chromatography on silica gel eluting with EtOAc(5)-hexane(95) to afford 6-1 as a clear oil. R_f 0.5 (silica gel eluting with EtOAc(30)-hexane(70)).

Methyl 2-S-(Benzylloxycarbonylamino)-3-[4-(3-iodopropoxyphenyl)propionate (6-2).

45 A solution of 6-1 (0.6 g, 1.5 mmol) in acetone was treated with sodium iodide (1.1 g, 7.5 mmol) and the resulting solution was heated at reflux for 16 hours. The reaction mixture was then diluted with ether, washed with water, brine and dried (Na_2SO_4). Solvent removal gave an oil that was purified by flash chromatography on silica gel eluting with hexane(90)- EtOAc (10) to give 6-2 as a clear oil.

¹H NMR (300 MHz, CDCl₃) δ 1.85–2.08 (4H, m), 3.04 (2H, m), 3.26 (2H, t), 3.71 (3H, s), 3.95 (2H, t), 4.60 (1H, m), 5.00–5.21 (3H, m), 6.78 (2H, d), 6.99 (2H, d), 7.33 (5H, m).

Methyl 2-S-(N-Benzylxycarbonylamino)-3-[4-(2,6-dimethylpiperazin-4-yl)propyloxyphenyl]propionate (6-3).


55 A solution of 6-2 (0.1 g, 0.2 mmol) and 2,6-dimethylpiperazine (0.068 g, 0.6 mmol) in 1 ml THF was stirred at room temperature for 20 hours. The solvents were removed at low pressure to provide 6-3 as a clear oil. ¹H NMR (300 MHz, CDCl₃) δ 1.45 (4H, d), 1.82 (3H, m), 2.65 (2H, m), 2.79 (2H, m), 3.05 (1H, m), 3.18 (2H, bd), 3.60 (1H, m), 3.72 (3H, s), 3.96 (2H, m), 4.62 (1H, m), 5.10 (2H, s), 5.21 (1H, m), 6.79 (2H, d), 7.00 (2H, d).

d), 7.35 (5H, bs).

2-(N-Benzylcarbonylamino)-3-[4-(2,6-dimethylpiperazin-4-yl)propyloxyphenyl]propionic acid (6-4).

5 6-3 (0.090 g, 0.2 mmol) in methanol was treated with 1N NaOH (0.7 ml) at room temperature for 16 hours. The solvent was removed to give crude acid which was purified by flash chromatography on silica gel eluting with isopropanol(10)-NH₄OH(1)-H₂O(1) to provide pure 6-4, R_f 0.25.
10 ¹H NMR (300 MHz, CD₃OD) δ 1.65-1.85 (4H, m), 2.60-2.70 (2H, m), 2.80-2.95 (6H, m), 3.11 (8H, m), 3.52 (2H, m), 3.65-3.75 (2H, m), 3.82 (2H, t), 4.17 (1H, m), 4.70 (2H, s), 4.85 (2H, m), 6.63 (2H, d), 6.92 (2H, d), 7.10 (5H, bs).

SCHEME 7



Methyl 2-S-(N-Benzylloxycarbonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)propyloxyphenyl]propionate (7-1).

5 A solution of 1-1 (4.0 g, 2.6 mmol) and 3-(N-Boc-piperidin-4-yl)propyl iodide (1.1 g, 3.3 mmol) in 40 ml DMF
 was treated with cesium carbonate (0.4 g, 1.35 mmol) and the resulting solution was stirred at room temperature
 for 20 hours. The solvent was removed and the residue was taken up in EtOAc, washed with water, brine and
 dried (Na_2SO_4). Solvent removal provided a residue that was purified by flash chromatography on silica gel
 eluting with 4:1 hexane(80)-EtOAc(20) to give pure 7-1 as a clear oil.
 10 ^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.37-1.45 (11H, m), 1.65-1.82 (4H, m), 2.68 (2H, m), 3.03 (2H, m),
 3.71 (3H, s), 3.90 (2H, t), 4.08 (2H, bd), 4.61 (1H, m), 5.10 (1H, s), 5.18 (1H, m), 6.79 (2H, d), 7.00 (2H, d),
 7.35 (5H, bs).

2-(S)-(N-Benzylloxycarbonylamino)-3-[4-(N-t-butyloxycarbonylpiperidin-4-yl)propyloxyphenyl]propionic acid
 (7-2).

15 7-1 (0.5 g, 0.9 mmol) in methanol (12 ml) was treated with 1N NaOH (3 ml) at room temperature for 16 hours.
 The solvent was then removed and the residue acidified with 5% KHSO_4 solution. This was extracted with
 EtOAc several times and the combined organic extracts were washed with brine and dried (Na_2SO_4). Solvent
 removal gave 7-2 as a clear oil.
 20 ^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.37-1.52 (12H, m), 1.62-1.85 (5H, m), 2.66 (2H, t), 3.10 (2H, m),
 4.89 (2H, t), 4.10 (4H, m), 4.62 (1H, m), 5.09 (1H, s), 5.19 (1H, m), 6.79 (2H, d), 7.03 (2H, d), 7.34 (5H, bs).

Methyl 3-S-(N-Benzylloxycarbonylamino)-4-[4-(N-t-butyloxycarbonylpiperidin-4-yl)propyloxyphenyl]butanoate
 (7-3).

25 To a stirred solution of 7-2 (1.6 g, 2.9 mmol) in EtOAc at -15°C was added isobutylchloroformate (2.9 mmol)
 and N-methylmorpholine (2.9 mmol) and the resulting solution was stirred for 0.5 hours at -15°. Then,
 diazomethane (5.0 mmol in Et_2O) was added and the reaction mixture was stirred at 0° for 20 minutes. The
 reaction mixture was purged with argon, diluted with EtOAc and washed with water. The organic phase was
 dried (MgSO_4) and the solvent removed to provide the desired diazoketone.
 30 ^1H NMR (300 MHz, CDCl_3) δ 1.10 (2H, m), 1.35-1.50 (12H, m), 1.55-1.85 (6H, m), 2.68 (2H, bt), 2.95 (2H, d),
 3.90 (2H, t), 4.09 (3H, m), 4.42 (1H, m), 5.06 (1H, m), 5.20 (1H, m), 5.35 (1H, m), 6.80 (2H, d), 7.06 (2H, d),
 7.35 (5H, bs).

35 This diazoketone (1.63 g, 2.9 mmol) was dissolved in CH_3OH (20 ml) and treated at room temperature with
 a CH_3OH solution (5 ml) of silver benzoate (0.22 mg, 0.96 mmoles) and triethylamine (1.25 ml). After a few
 minutes the reaction became black with gas evolution apparent. After 0.5 hours the solvent was removed and
 the residue was purified by flash chromatography on silica gel eluting with 4:1 hexane(80) EtOAc(20) to give
 7-3 as an oil.
 40 ^1H NMR (300 MHz, CDCl_3) δ 1.12 (2H, m), 1.37-1.47 (12H, m), 1.60 (2H, s), 1.65-1.83 (4H, m), 2.49 (2H, m),
 2.62-2.91 (4H, m), 3.67 (3H, s), 3.90 (2H, t), 4.03-4.20 (4H, m), 5.08 (2H, s), 5.24 (1H, m), 6.79 (2H, d), 7.05
 (2H, d), 7.32 (5H, bs).

3-S-(N-Benzylloxycarbonylamino)-4-[4-(piperidin-4-yl)propyloxyphenyl]butanoic acid (7-4).

45 A solution of 7-3 (0.3 g, 0.53 mol) was treated with 1N NaOH (1.7 ml) and the resulting mixture was stirred
 at room temperature for 16 hours. The solvent was removed and the residue acidified with 5% aq KHSO_4 solvent
 and this was extracted several times with EtOAc. The combined organics were washed with brine, dried
 (Na_2SO_4) and the solvent removed to give the desired acid.

50 ^1H NMR (300 MHz, CD_3OD) δ 1.10 (2H, m), 1.40-1.52 (12, m), 1.65-1.84 (6H, m), 2.54-2.93 (8H, m), 3.92 (2H,
 t), 4.05-4.12 (3H, m), 5.10 (2H, s), 6.71 (2H, d), 7.08 (2H, d), 7.35 (5H, m).

55 This acid was dissolved in CH_2Cl_2 (4 ml) and anisole (0.41 mmole) was added, followed at 0° with trifluoroacetic acid (2 ml). After 2.5 hours stirring at 0°, the solvents were removed and the residue purified by
 flash chromatography on silica gel eluting with $\text{EtOH}(10\text{-NH}_4\text{OH}(1\text{-H}_2\text{O}))$ to give pure 7-4 as a white solid.

55 ^1H NMR (300 MHz, CD_3OD) δ 1.3-1.5 (4H, m), 1.6 (1H, m), 1.75-1.85 (2H, m), 1.95 (2H, d), 2.54 (2H, m), 2.72
 (2H, m), 2.93 (2H, t), 3.32 (6H, m), 3.92 (2H, t), 4.11 (1H, m), 4.95 (2H, m), 6.75 (2H, d), 7.05 (2H, d), 7.25 (5H,
 m).

5

10

15

20

25

30


35


40

45

50

SCHEME 8






Methyl 2-S-(Hexanoylamino)-3-(4-iodophenyl)propionate (8-2)

15 A suspension of 8-1 (1.01 g, 2.96 mmoles) in 20 ml CHCl_3 was cooled to 0° and pyridine (1.43 ml, 17.7 mmoles) was added followed by hexanoylchloride (1.25 ml, 8.88 mmoles). After 20 minutes all 8-1 was consumed. Water (25 ml) was then added carefully and this mixture was extracted with EtOAc (150 ml). The separated organic phase was washed with 10% KHSO_4 , brine, dried (Na_2SO_4) and the solvent was removed to give a white solid. This was purified by flash chromatography on silica gel eluting with 5% $\text{Et}_2\text{O}/\text{CHCl}_3$ to give pure 8-2 (1.07 g) as a white solid.

20 $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 0.88 (3H, t), 1.27 (4H, m), 1.60 (2H, m), 2.09 (2H, t), 3.05 (2H, m), 3.75 (3H, s), 4.88 (1H, m), 5.93 (1H, m), 6.83 (2H, d), 7.60 (2H, d).



5-(N-t-Butyloxycarbonyl)piperidin-4-yl)-1-trimethyl-1-silylpent-3-ene-1-yne (8-4).

40 A suspension of 3-trimethylsilyl-2-propynyltriphenyl phosphonium bromide (3.0 g, 6.62 mmoles) (Aldrich) in 50 ml THF was cooled to -78° and treated with $n\text{-BuLi}$ (6.62 mmoles) dropwise. The resulting solution was allowed to warm to -40° and was then stirred for 0.5 hours to give a deep red solution. After cooling to -78°C the reaction mixture was treated with 8-3 (1.07 g, 4.73 mmoles) in 15 ml THF and was allowed to warm to 0° with stirring for 1 hour. The reaction was quenched with 50 ml H_2O and this was extracted with EtOAc (200 ml). The organic phase was separated, dried (Na_2SO_4) and stripped to provide as residue that was purified by flash chromatography on silica gel eluting with 10% $\text{EtOAc}/\text{hexane}$ to provide pure 8-4, (2.02 g), R_f = 0.3.

45 $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 0.10 (9H, s), 0.70-1.10 (4H, m), 1.10-1.40 (13H, m), 1.40-1.60 (3H, m), 1.83 (3H, m), 2.40-2.60 (3H, m), 3.85 (3H, m), 5.35 (1H, t), 6.00 (1H, m).




5-(N-t-Butyloxycarbonyl)piperidin-4-yl)pent-3-en-1-yn-1-yl (8-5)

55 A solution of 8-4 (0.815 g, 2.54 mmoles) in 60 ml THF was treated with 12 ml H_2O and lithium hydroxide hydrate (0.96 g, 2.28 mmoles). The reaction mixture was stirred at room temperature for 6 hours during which time the color became dark orange. The reaction mixture was then diluted with Et_2O (75 ml) and the aqueous

phase was separated and washed with 3x75 ml Et₂O. The combined organic extracts were washed with brine, dried and stripped. The resulting residue was purified by flash chromatography on silica gel eluting with 10% EtOAc/hexanes to give 0.63 g pure 8-5.

5 ¹H NMR (300 MHz, CDCl₃) δ 1.0-1.25 (3H, m), 1.25-1.60 (11H, m), 1.60-1.75 (3H, m), 2.06 (2H, t), 2.30 (1H, t), 2.60-2.78 (2H, m), 4.07 (2H, m), 5.51 (1H, m), 6.22 (1H, m).




15 Methyl 2-S-(Hexanoylamino)-3-[4-(5-N-t-butyloxycarbonylpiperidin-4-yl)pent-3-ene-1-ynephenyl]propionate (8-6).

20 A solution of 8-5 (0.3 g, 1.2 mmoles) and 8-2 (0.58 g, 1.4 mmoles) in diethylamine (6 ml) was purged with N₂ and bis-triphenylphosphine palladium chloride (0.049 g, 0.07 mmoles) was added followed by cuprous iodide (7 mg, 0.035 mmoles) and the suspension was purged again. After several minutes the reaction mixture became homogeneous and this solution was stirred for 16 hours at room temperature.

25 The solvent was removed at high vacuum and the residue was dissolved in pH 7 buffer and extracted with Et₂O. The organic extract was washed with 10% KHSO₄, brine, then dried (Na₂SO₄) and stripped. The residue was purified by flash chromatography on silica gel eluting with 20% EtOAc/hexanes to give 0.28 g pure 8-6. R_f = 0.3 (20% EtOAc, hexanes).

1H NMR (300 MHz, CDCl₃) δ 0.90 (3H, m), 1.05-1.40 (9H, m), 1.52 (6H, s), 1.58-1.75 (4H, m), 2.07 (2H, m), 1.70 (2H, m), 3.14 (2H, m), 3.75 (2H, m), 4.10 (2H, m), 4.89 (1H, m), 5.70 (1H, m), 5.94 (1H, m), 6.18 (1H, m), 7.03 (2H, m), 7.38 (2H, m).



2-S-(Hexanoylamino)-3-[4-(5-Piperidin-4-yl)pentylphenyl]propionic acid (8-7)

40 8-6 (0.275 g, 0.52 mmoles) was dissolved in EtOH and 2 ml of H₂O was added along with 5 drops of HOAc. Pd-C (100 mg) was added and the resulting suspension was hydrogenated on a Paar shaker (50 psi) for 4 hours. The reaction mixture was filtered through Solka-Floc and the resulting solvent was removed. The resulting residue was purified by flash chromatography on silica gel eluting with 35% EtOAc/hexanes to give 0.22 g of methyl 2-S-hexanoyl amino-3-[4-5-N-t-butyloxycarbonylpiperidin-4-yl]pentylphenyl propionate.

45 ¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, t), 1.00-1.35 (12H, m), 1.45 (9H, s), 1.50-1.65 (6H, m), 2.15 (2H, t), 2.50-2.65 (4H, m), 3.05 (2H, m), 3.71 (3H, s), 4.04 (2H, m), 4.83 (1H, m), 5.96 (1H, m), 6.98 (2H, d), 7.04 (2H, d).

50 This ester (0.17 g, 0.32 mmoles) was suspended in 10 ml of 1:1 THF/H₂O and CH₃OH (2 ml), lithium hydroxide hydrate (0.067 g, 1.6 mmoles) was added and the reaction was stirred for 2.0 hours at room temperature. The solvent was then removed and the residue was taken up in H₂O. This was acidified to pH 2-3 with 10% KHSO₄, and extracted with EtOAc. The organic extract was washed with brine, dried (Na₂SO₄) and stripped to give 0.050g of the desired acid.

55 ¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, m), 0.95-1.42 (15 H, m), 1.47 (9H, s), 1.50-1.70 (7H, m), 2.18 (2H, m), 2.48-2.72 (5H, m), 5.02-5.30 (2H, m), 4.03 (2H, m), 4.84 (1H, m), 6.05 (1H, m), 7.06 (4H, s).

60 This acid (0.15 g, 0.29 mmoles) was dissolved in EtOAc (25 ml), cooled to -70° and treated with HCl gas for 10 minutes. The temperature was allowed to rise to -20° over 0.5 hr. The reaction mixture was purged with N₂ and the solvent was removed. The residue purified by flash chromatography on silica gel eluting with 9:1:1 EtOH/H₂O/NH₄OH to give pure 8-7, 0.040 g as a white solid.

65 ¹H NMR (300 MHz, CD₃OD) δ 0.78 (3H, t), 1.05-1.30 (9H, m), 1.32-1.56 (4H, m), 1.74 (2H, d), 2.03 (2H, m),

2.42 (2H, m), 2.70-2.85 (3H, m), 3.04 (1H, dd), 3.21 (2H, m), 4.38 (1H, m), 6.92 (2H, d), 7.00 (2H, d).


In the above Schemes and Examples, various reagent symbols have the following meanings:

5 BOC: t-butoxycarbonyl.
 Pd-C: Palladium on activated carbon catalyst.
 DMF: Dimethylformamide.
 CBZ: Benzyloxycarbonyl.
 BOP: Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.
 EtOAc: ethyl acetate
 10 DMF: dimethylformamide
 CH₂Cl₂: methylene chloride
 CHCl₃: chloroform
 MeOH: methanol
 HOAc: acetic acid

Suitable alternative protecting groups that can be used in the preparation of the present invention include
 15 benzyl ester, cyclohexyl ester, 4-nitrobenzyl ester, t-butyl ester, 4-pyridylmethyl ester, benzyloxycarbonyl, iso-nicotinyloxycarbonyl, O-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, adamantlyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl and 9-fluorenylmethoxycarbonyl.

In addition to those compounds specifically exemplified above, additional compounds of the present invention are set forth in tabular form below. These compounds are synthesized by use of the synthetic routes and methods described in the above Schemes and Examples and variations thereof well known to those of ordinary skill in the art, and not requiring undue experimentation. All variables listed in the Tables below are with reference to the following generic structure:

25



30

35

40

45



50



55



Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
18	C ₂ H ₅ O ₂ CCH ₂	HN	-CH ₂ CO ₂ C ₆ H ₅	-H	-(CH ₂) ₃ OCH ₃	-P(OH) ₂
19	CH ₃ CH ₂	N	-H	-(CH ₂) ₂ OCH ₃	-CH ₃	-P(CC ₆ H ₅) ₂
20	CH ₃ COCH ₂	HN	-CF ₂ CF ₃	-H	-C ₂ H ₅	-P(CC ₂ H ₅) ₂
21	C ₆ H ₅ CH ₂	S=O	-(CH ₂) ₂ NH	-CH ₃	-C ₃ H ₇	-P(OH) ₂
22			C ₂ H ₅			-CH ₃
23	H ₂ N-C	NH	-H	-CCH ₂ C ₆ H ₅	-CH ₂ C ₆ H ₅	-CO ₂ CH ₃
						-H

Example	R ⁷	X	Y	Z	m	n	p
18	-CH ₃	-C≡C-	$\begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{C}_6\text{H}_3 \\ \\ \text{CH}_2 \end{array}$	-CH-	1	1	1
19	-C ₆ H ₅	$\begin{array}{c} \text{CH}_3 \\ \\ \text{C}=\text{C}- \\ \\ \text{CH}_2\text{CN} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{C}-\text{NH} \end{array}$	-CH ₂	2	3	1
20	-H	$\begin{array}{c} \text{CHOCH}_3 \\ \\ \text{CH}_2\text{CN} \\ \\ \text{CH}_2- \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{NHC}- \end{array}$	$\begin{array}{c} \text{OCH}_3 \\ \\ \text{CH}_2- \end{array}$	4	1	1
21	-OCH ₃	$\begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{N}-\text{C}- \\ \\ \text{O} \end{array}$	-CH ₂	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_2- \end{array}$	6	2	2
22	-H	$\begin{array}{c} \text{O} \\ \\ \text{C}-\text{NH} \\ \\ \text{C}_6\text{H}_5 \end{array}$	-CH ₂	-O-	5	1	5
23	-CH ₃			$\begin{array}{c} \text{CH}_3 \\ \\ \text{N} \\ \\ \text{C}_6\text{H}_5 \end{array}$	-S-	5	2

Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
24	CH ₃ CO ₂ H	S	-H	-(CH ₂) ₂ C ₆ H ₅	-CO ₂ C ₆ H ₅	-CF ₃
25	CH ₃ OH	-CC ₂ H ₅	-H	S	-COC ₂ H ₅	-H
26	H ₂ NC-NH-	-H	-H	NC	-S	-CO ₂ C ₆ H ₅
27	H ₂ NC-NH-	-CH ₂ SO ₂ C ₆ H ₅	-CF ₃	-CH ₂ SO ₂ CH ₃	-COCH ₂ C ₆ H ₅	-C ₂ H ₅
28	H ₂ NC-NH-	-H	-H	-(CH ₂) ₂ NH	-COCH ₂ C ₆ H ₅	-CH ₂ CO ₂ C ₆ H ₅
29	CH ₂ OH	CH ₂ OH	-H	-(CH ₂) ₂ CH ₂ OH	-CH ₂ CF ₃	-H
30	H ₃ CCN	O	-H	-(CH ₂) ₂ CH ₂	NO ₂	-H ₃ C
31	O	-CH ₂ CH ₂ CN	-H	-CH ₂ C(=O)C ₆ H ₄ N	-CO ₂ H	-CH ₂ C ₆ H ₅

Example	R ⁷	X	Y	Z	m	n	p
24	-H	-O-	C ₄ H ₉ -CH-	-SO-	2	4	3
25	-OCH ₃	O	CH ₃ C ₆ H ₅ -CH-	-SO ₂ -	1	3	1
26	-CN	S	CO ₂ C ₂ H ₅ -CH-	-NH-	2	2	2
27	-H			-O-	CH ₃ -N-	3	3
28	-CH ₃			CH ₂ C ₆ H ₅ -N-	C ₄ H ₉ -N-	4	1
29	-H			CH ₃ -CH-	CH ₂ C ₆ H ₅ -N-	0	5
30	-(CH ₂) ₂ C ₆ H ₅			C ₆ H ₅ -CH-	C ₄ H ₉ -N-	3	2
31	-H			CN -CH-	-O-	-	1
						2	4

Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
32		-H	-(CH ₂) ₂ CN	-C ₆ H ₄ 7		-C ₃ H ₇
33	C ₆ H ₅ CH ₂ NHC-	-CH ₂ OC ₆ H ₅	-C ₃ H ₇	-(CH ₂) ₂ CCH ₃	-CO ₂ CH ₃	-H
34		-t-Bu	-CH ₂ C ₆ H ₅	-(CH ₂) ₂ OC ₆ H ₅	-CO ₂ H	-CH ₃
35	H ₂ CNCH ₂ H ₃		-H	-CH ₃	-CO ₂ H	-C ₂ H ₅
36	H ₃ C		-H		-CO ₂ C ₄ H ₉	-OC ₃ H ₇
37	H ₂ N-C	N-CN	-H	-C ₄ H ₉	-(CH ₂) ₂ NHCCCH ₃	-CO ₂ H
38		-CH ₂ C ₆ H ₅	-H	-(CH ₂) ₄ OC ₂ H ₅	-CO ₂ C ₂ H ₅	-CH ₃
39		-(CH ₂) ₂ OC ₂ H ₅	-C ₂ H ₅		-CH ₂ CH ₂ C ₆ H ₅	-P(OH) ₃






		R ⁷	X	Y		m	n	p
5					2	6	4	6
10					-C-			
15		32	-H					
20					-C-			
25					-C=C-	3	1	3
30						1	1	1
35					-C-			
40								
45								
50								
55								

Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
40	CH ₃ CH ₂ NH-C-NH-	N-CH ₃	-H ₂ C-C(=O)N-	-CH ₃	-CH ₂ CH ₂ CO ₂ -1-Pr	-O-C(=O)O ₂
41		-CH ₂ SO ₂ CH ₃	-CH ₂	-CH ₂	-O-C(=O)CH ₂	-F
42	H ₂ C-NH-		-CH ₂ CD ₂ CH ₃		-POC(=O)H ₂	-CN
43	N ² CH ₂ C ₆ H ₅	-CH ₂ SC ₆ H ₅	-CH ₂ OCH ₃	-CH ₂ CH ₂ OH	-O-C(=O)CH ₂ C ₆ H ₅) ₂	-C ₂ H ₅
44	Et ₂ N-	-CH ₂ OC ₃ H ₇	-H	-	-CO ₂ H	-H
45			-CC ₂ H ₅	-CH ₂ C(=O)H ₂	-CO ₂ -i-Pr	-CH ₂ CN
46	CH ₃ N	-CH ₂) ₂ NHCH ₃	-CF ₃		-CO ₂ C ₆ H ₅	-CH ₃
47	(F ₃ CH ₂ C)HN-	-H	-C ₃ H ₇	-C ₆ H ₅	-CO ₂ H	-CO ₂ CH ₃
48	H ₂ N-	-t-Bu	-H		-CO ₂ CH ₃	-F

50

55

Example	R ⁷	X	Y	Z	m	n	P
40	-CH ₃	-NH	-SO ₂	-O-	2	4	1
41	-OH	-NCH ₂ C ₆ H ₅	-SO ₂	O=C-	3	1	0
42	-H	-C=	-CH ₂ -	S=H	1	1	1
43	-H	-CH ₂ -	-C=	O=	-NHCO-	3	4
44	-CF ₃ CF ₃	-O-	-CH ₂ -	O=	-NHCO-	2	0
45	-H	H ₃ C-F -C=C-	-SO ₂	O=CCH ₃	-C-N-	1	3
46	-OH	O=CCH ₃ -C-N-	-CH ₂ -	-	10	2	2
47	-H	-CH ₂ -	-CH	S=H	-C-	0	2
48	-CF ₃	-NH	-CH ₂ -	O=C	-C-	3	1

Example	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
49	NHCH ₂	O -CH ₂ CCH ₃	-		-CO ₂ C ₂ H ₅	-CH ₂ NO ₂
50	NH H ₂ NC-NH	-CH ₃ SC ₂ H ₅	-H	-C ₂ H ₅	-CO ₂ C ₃ H ₇	-H
51	C ₂ H ₅ O ₂ CCH ₂ CH ₂ -NH	-CF ₃	-H	-C ₄ H ₇	-CO ₂ CH ₂ C ₆ H ₅	
52		-CH ₃		-C ₂ H ₅	-CO ₂ CCH ₃	-OC ₂ H ₅
53	H ₃ C- 	-CH ₂ CN	-CH ₂ CN	-C ₆ H ₅	-CO ₂ COCCH ₃	
54	S H ₃ CCRNH ₂ CH ₂ CN-	CH ₃	-CH ₂ CF ₃		-C ₇ H ₁₃	-CO ₂ COC(CH ₃) ₃
55	H ₃ C ₂ CHNR ₂ CH ₂ CN-	H ₃ C ₄ H ₃ C		-C ₃ H ₅	-C ₆ H ₇	-CH ₂ CO ₂ H
56		-H	-CH ₂ C ₃ H ₇	-C ₃ H ₉		-CC ₆ H ₅
57	H ₃ COOC(CH ₂) ₂ -		-H	-(CH ₂) ₂ C ₆ H ₅	-(CH ₂) ₂ -O-C ₆ H ₅	-C ₆ H ₅

45

50

55

5

10

15

20

25

30

35

50

55

Example	R ⁷	X	Y	Z	m	n	p
49	-H	-CH ₂	-CH ₂	-	2	2	2
50	$\begin{matrix} \text{O} \\ \text{H} \end{matrix}$ -CH ₂ NHCCH ₃	-CH ₂ -	COCH ₃ -N-	C ₄ H ₉ -CH ₃	6	0	0
51	-H	-S-	-CH ₂ -	CH ₃ -CH	3	1	1
52	-CH ₃	-SO	-CH ₂ -	-	0	0	5
53	-F	-SO ₂	-NH	-	8	1	2
54	$\begin{matrix} \text{S} \\ \text{H} \end{matrix}$ -COC ₂ H ₅	O -C-	-NH	C ₃ H ₇ -CH	4	2	2
55	$\begin{matrix} \text{O} \\ \text{H} \end{matrix}$ -CH ₂ CCCH ₃	-C-	-NH	-CH ₂ -CH ₂ CH ₃	6	1	3
56	-F	-CH=CH-	-NCH ₃	F ₃ C -CH ₂	2	2	2
57	-H	-C≡C-	-NCH ₃	$\begin{matrix} \text{O} \\ \text{C}_2\text{H}_5 \end{matrix}$ -CH ₂ CH	3	4	1

EXAMPLE 58

5 Blood was drawn into 0.1 volumes of acid-citrate-dextrose (85 mM sodium citrate, 64 mM citric acid, 110 mM dextrose) by venipuncture from normal human volunteers. Platelet-rich plasma was prepared by centrifugation at 400 x g for 12 minutes. PGE1 (5 mg/ml) was added and platelets were collected by centrifugation at 800 x g for 12 minutes. The platelet pellet was resuspended into human platelet buffer (140 mM NaCl, 7.9 mM KCl, 3.3 mM Na₂HPO₄, 6 mM HEPES, 2% bovine serum albumin, 0.1 % dextrose, pH 7.2) and filtered over Sepharose 2B that was previously equilibrated in human platelet buffer. Platelets were counted and adjusted to 2 x 10⁸/ml with human platelet buffer. Human fibrinogen (10-100 mg/ml) and CaCl₂ (1 mM) were added and aggregation was initiated by the addition of 10 mM ADP. Aggregation was monitored by the initial rate of increase of light transmittance.

10 While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of the mammal being treated for severity of clotting disorders or emboli, or for other indications for the compounds of the invention indicated above.


15 Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of 20 formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

25

Claims

1. A compound of the structural formula

30




35


40 and the pharmaceutically acceptable salts thereof, wherein

R¹ is a four to eight member heterocyclic ring containing 1, 2, 3 or 4 heteroatoms wherein said heteroatoms are N, O or S and wherein said heterocyclic ring is optionally substituted at any atom by H, R⁶ or R⁷; NR⁶R⁷

45



50



55



wherein R⁶ and R⁷ are independently

hydrogen and

unsubstituted or substituted C₀₋₁₀ alkyl and cycloalkyl wherein said substituents are C₁₋₁₀ alkoxy,

5 C₁₋₁₀ alkoxyalkyl,
 C₁₋₁₀ alkoxyalkyloxy,
 C₁₋₁₀ alkoxy carbonyl,
 C₁₋₁₀ alkyl carbonyl,
 C₄₋₁₀ aralkyl carbonyl,
 C₁₋₁₀ alkylthio carbonyl,
 C₁₋₁₀ aralkylthio carbonyl, thiocarbonyl,
 C₁₋₁₀ alkoxythio carbonyl, aryl,
 10 a 5 to 6 membered saturated heterocyclic ring containing 1, 2, 3 or 4 heteroatoms wherein
 said heteroatoms are taken from the group consisting of
 N, O and S,
 C₁₋₄ alkanoyl amino,
 C₁₋₆ alkoxy carbonyl-C₀₋₆ alkyl amino,
 15 C₁₋₁₀ alkylsulfonyl amino,
 C₄₋₁₀ aralkylsulfonyl amino,
 C₄₋₁₀ aralkyl,
 C₁₋₁₀ alkaryl,
 C₁₋₁₀ alkylthio,
 20 C₄₋₁₀ aralkylthio,
 C₁₋₁₀ alkylsulfinyl,
 C₄₋₁₀ aralkylsulfinyl,
 C₁₋₁₀ alkylsulfonyl,
 25 C₄₋₁₀ aralkylsulfonyl, aminosulfonyl,
 C₁₋₁₀ alkylaminosulfonyl,
 C₄₋₁₀ aralkylsulfonyl amino,
 oxo,
 thio,
 30 unsubstituted and mono- and di-substituted 1-ethenyl, 2-ethenyl and 3-propenyl wherein
 said substituents are selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀
 aralkyl,
 carboxy,
 hydroxy,
 35 amino,
 C₁₋₆ alkyl amino,
 C₁₋₆ dialkyl amino,
 halogen, where halogen is defined as F,
 Cl, Br or I,
 40 nitro, and
 cyano,
 and further wherein said N can additionally be substituted to form a quaternary ammonium ion whe-
 rein said substituent is as previously defined for R⁶ and R⁷;
 R² and R³ are independently
 45 hydrogen,
 aryl and
 unsubstituted and substituted C₀₋₁₀ alkyl and cycloalkyl wherein said substituent is
 C₁₋₁₀ alkoxyalkyl,
 aryl,
 50 a 4 to 8 membered saturated heterocyclic ring system containing 1, 2, 3 or 4 hetero atoms,
 wherein said hetero atoms are taken from the group consisting of N, O and S,
 C₄₋₁₀ aralkyl,
 C₁₋₁₀ alkaryl,
 C₁₋₁₀ alkylthio,
 55 C₄₋₁₀ aralkylthio,
 C₁₋₁₀ alkylsulfinyl,
 C₄₋₁₀ aralkylsulfinyl,

5 C₁₋₁₀ alkylsulfonyl,
 C₄₋₁₀ aralkylsulfonyl, carboxy,
 C₁₋₁₀ alkylcarbonyl,
 C₁₋₁₀ alkylthiocarbonyl,
 C₄₋₁₀ aralkylcarbonyl,
 C₄₋₁₀ aralkylthiocarbonyl,
 C₁₋₆ alkoxy carbonyl,
 C₄₋₁₀ aralkoxycarbonyl,
 10 C₁₋₆ alkoxy,
 C₁₋₆ alkoxy carbonyl-C₁₋₄ alkyl,
 C₄₋₁₀ aralkoxycarbonyl-C₁₋₄ alkyl,
 C₄₋₁₀ aralkoxy,
 C₁₋₆ alkylamino,
 15 C₁₋₁₂ dialkylamino,
 C₁₋₆ alkanoylamino,
 C₄₋₁₀ aralkanoylamino,
 C₄₋₁₀ aralkylamino,
 20 R⁴ is
 aryl,
 C₁₋₁₀ alkyl or cycloalkyl,
 C₄₋₁₀ aralkyl,
 C₁₋₁₀ alkoxyalkyl,
 25 C₁₋₁₀ alkaryl,
 C₁₋₁₀ alkylthioalkyl,
 C₁₋₁₀ alkoxythioalkyl,
 C₁₋₁₀ alkylamino,
 C₄₋₁₀ aralkylamino,
 30 C₁₋₁₀ alkanoylamino,
 C₄₋₁₀ aralkanoylamino,
 C₁₋₁₀ alkanoyl,
 C₄₋₁₀ aralkanoyl, and
 35 unsubstituted or substituted C₁₋₁₀ carboxyalkyl wherein said substituent is aryl or C₁₋₁₀ aralkyl;
 further wherein any of the substituents for R⁴ may be substituted by a substituent selected from the group
 as defined for R⁶;
 R⁵ is
 40 a four to eight member saturated or unsaturated heterocyclic ring containing 1, 2, 3 or 4 heterocyclic
 atoms wherein said heteroatoms are N, O and S and




55 wherein R⁸ is
 hydroxy,
 C₁₋₁₀ alkyloxy,
 C₁₋₁₀ alkaryloxy,
 C₄₋₁₀ aralkyloxy,
 C₄₋₁₀ aralkylcarbonyloxy,
 C₁₋₁₀ alkoxyalkyloxy,


C₁₋₁₀ alkoxyalkylcarbonyloxy,
C₁₋₁₀ alkoxy carbonylalkyl,
C₁₋₁₀ alkylcarbonyloxyalkyl oxy,
an L- or D-amino acid joined by an amide linkage or
an L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said
amino acid is esterified by C₁₋₆ alkyl or C₄₋₁₀ aralkyl,





20 wherein R⁹ and R¹⁰ are selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and C₄₋₁₀ aralkyl; X and Y are optional substituents that, when present are independently NR⁶.



SO₂.




35 -C=C-,
a 4- to 8-membered ring containing 0, 1, 2, 3 or 4 heteroatoms chosen from N, O and S, wherein
said ring is independently substituted at any atom with R⁶
aryl,
or



Z is an optional substituent that, when present, is independently chosen as defined for X and Y;
m is an integer of from zero to ten;
n is an integer of from zero to ten; and
p is an integer of from zero to three.

2. A compound of the structural formula



and the pharmaceutically acceptable salts thereof, wherein
R¹ is

a four to eight member heterocyclic ring wherein said heteroatoms are N, O or S and wherein said heterocyclic ring is optionally substituted by C₁₋₁₀ alkyl; or

15 NR⁶R⁷ wherein R⁶ and R⁷ are independently

hydrogen,

unsubstituted or substituted C₁₋₁₀ alkyl wherein said substituent is

C₁₋₁₀ alkoxy carbonyl,

aryl,

20 C₀₋₆ dialkylamino-C₁₋₁₀ alkyl,

C₄₋₁₀ aralkyl,

and further wherein said N can additionally be substituted to form a quaternary ammonium ion wherein said substituent is as previously defined for R⁶ and R⁷;

25 R² and R³ are independently

hydrogen,

C₁₋₄ alkyl or C₄₋₁₀ aralkyl;

R⁴ is

aryl,

C₁₋₁₀ alkyl or cycloalkyl,

C₄₋₁₀ aralkyl,

C₁₋₁₀ alkoxyalkyl or

unsubstituted or substituted C₁₋₁₀ carboxyalkyl wherein said substituent is aryl or C₁₋₁₀ aralkyl;

R¹¹ is


hydrogen or

C₁₋₁₀ alkyl;

X and Y are independently

0,

SO₂,




45

aryl,

a 5- or 6-membered ring containing 0, 1 or 2 heteroatoms chosen from N, O and S wherein said ring is independently substituted at any atom with R⁶;

Z is an optional substituent that, when present, is



55




C₁₋₁₀ straight or branched alkyl;

m is an integer of from zero to eight;

n is an integer of from zero to two; and

p is an integer of from zero to two structural formula

3. A compound of the structural formula



R¹ is

5 a six member saturated heterocyclic ring containing one or two heteroatoms wherein said heteroatoms are N or O and wherein said heterocyclic ring is optionally substituted by C₁₋₃ alkyl; or NR⁶R⁷ wherein R⁶ and R⁷ are independently

hydrogen or
C₁₋₁₀ alkyl;

R⁴ is

aryl,
C₁₋₁₀ alkyl or
C₄₋₁₀ aralkyl;

X and Y are independently

C₁₋₁₀ alkyl or cycloalkyl

15 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{NHC}- \text{ or } -\text{C}\text{NH}-: \end{array}$

Z is an optional substituent that, when present, is

O, -NHCO-, or -CONH-


20 C₁₋₆ straight or branched alkyl;

m is an integer of from zero to six;

n is one or two; and

p is zero or one.

25 5. A compound of the structural formula



wherein

R¹ is

40 a six member saturated heterocyclic ring containing one or two heteroatoms wherein said heteroatoms are N;

NR⁶R⁷ wherein R⁶ and R⁷ are independently

H or
C₁₋₁₀ alkyl;

R⁴ is






aryl
C₁₋₁₀ alkyl
C₄₋₁₀ aralkyl;

Z is

50 $\begin{array}{c} \text{O} \\ \parallel \\ \text{O} \\ \text{O}, \text{ -NHC-}, \text{ -C-NH-}, \end{array}$

where m is an integer from two to six.

55 6. A compound as claimed in Claim 5, of the structural formula



7. A pharmaceutical composition comprising a compound as claimed in Claim 1 or Claim 6 and a pharmaceutically acceptable carrier.

55

8. The use of a compound as claimed in Claim 1 or Claim 6 for the manufacture of a medicament for blocking fibrinogen from acting as its platelet receptor site in a mammal.

9. The use of a compound as claimed in Claim 1 or Claim 6 for the manufacture of a medicament for the prevention or treatment of thrombus formation.
10. The use of a compound as claimed in Claim 1 or Claim 6 together with an anti-coagulant agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.
5
11. The use of a compound as claimed in Claim 1 or Claim 6 together with an anti-coagulant agent for the prevention or treatment of thrombus formation.
- 10 12. The use of a compound as claimed in Claim 1 or Claim 6 together with a fibrinolytic agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.
13. The use of a compound as claimed in Claim 1 or Claim 6 together with a fibrinolytic agent for the prevention or treatment of thrombus formation.
15
14. The use of a compound as claimed in Claim 1 or Claim 6 together with a platelet anti-aggregation agent for blocking fibrinogen from acting at its platelet receptor site in a mammal.
- 15 15. The use of a compound as claimed in Claim 1 or Claim 6 together with a platelet anti-aggregation agent for the prevention or treatment of thrombus formation.
20
16. The composition as claimed in Claim 7, further comprising at least one compound selected from the group consisting of platelet anti-aggregation agents, thrombolytic agents and anti-coagulation agents.

25

30

35

40

45

50

55